RESULT_COUNT: 387,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-10-16 13:45:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-134507241.html?.tsrc=rss,Agios Pharmaceuticals Inc NASDAQ/NGS:AGIO
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-10-13 12:04:23 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120423962.html?.tsrc=rss,Agios Pharmaceuticals Inc NASDAQ/NGS:AGIO
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : October 10, 2017",2017-10-10 14:57:39 +0000,http://finance.yahoo.com/r/1f8e3fc1-c72d-335b-95c3-129ded9d2f24/etfs-with-exposure-to-agios-pharmaceuticals-inc-october-10-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc (AGIO) CEO David P Schenkein Sold $5.6 million of Shares,2017-10-06 20:41:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3gIsmoBnlao/agios-pharmaceuticals-inc-agio-ceo-david-p-schenkein-sold-56-million-of-shares-cm856484,CEO of Agios Pharmaceuticals Inc AGIO David P Schenkein sold 80 000 shares of AGIO on 10 04 2017 at an average price of 70 14 a share The total sale was 5 6 million CEO of Agios Pharmaceuticals Inc AGIO David P Schenkein sold 80 000 shares of AGIO on 10 04 2017 at an average price
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-10-03 12:03:48 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120348424.html?.tsrc=rss,Agios Pharmaceuticals Inc NASDAQ/NGS:AGIO
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : September 29, 2017",2017-09-29 14:21:30 +0000,http://finance.yahoo.com/r/34a917ab-48fa-3202-b048-9382ce706ced/etfs-with-exposure-to-agios-pharmaceuticals-inc-september-29-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-09-27 12:05:52 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120552679.html?.tsrc=rss,Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan.  This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on September 25.
AGIO,AGIO:UW,BBG004P6MJ59,We Did The Math FBT Can Go To $141,2017-09-25 13:49:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nOjlFXN3X3Q/we-did-the-math-fbt-can-go-to-141-cm850278,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : September 18, 2017",2017-09-18 21:22:47 +0000,http://finance.yahoo.com/r/8160b02d-c1ca-37b6-a282-fec6d0f9f089/etfs-with-exposure-to-agios-pharmaceuticals-inc-september-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-09-12 12:01:59 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120159553.html?.tsrc=rss,Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
AGIO,AGIO:UW,BBG004P6MJ59,Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17,2017-09-07 17:29:23 +0000,http://finance.yahoo.com/r/97b0e62f-b5ab-3f00-9307-f03e998962e9/jazz-pharmaceuticals-on-the-street-analysts-recommendations-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology."
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : September 7, 2017",2017-09-07 16:15:27 +0000,http://finance.yahoo.com/r/08ca12ed-7127-316d-aa8c-730ae980eaf5/etfs-with-exposure-to-agios-pharmaceuticals-inc-september-7-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,New Drugs Approved In August,2017-09-07 05:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZoP1iaTzo4w/new-drugs-approved-in-august-20170907-00189,New Drugs Approved In August
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017",2017-09-06 12:47:23 +0000,http://finance.yahoo.com/r/522c80d7-be69-3053-9671-64bbcb3874fc/agios-pharmaceuticals-inc-agio-us-earnings-analysis-q2-2017-by-the-numbers-september-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Agios Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Agios Pharmaceuticals, Inc. – Xencor, Inc., BioMarin Pharmaceutical Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR, Exelixis, Inc., Alexion Pharmaceuticals, Inc., Eli Lilly and Company and Pfizer Inc. (XNCR-US, ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017",2017-09-05 11:30:00 +0000,https://finance.yahoo.com/news/agios-present-morgan-stanley-15th-113000697.html?.tsrc=rss,"CAMBRIDGE, Mass., Sept. 05, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to ..."
AGIO,AGIO:UW,BBG004P6MJ59,5 of the Most Hated Biotech Stocks on the Market: Are They Buys?,2017-09-01 16:08:00 +0000,http://finance.yahoo.com/r/bc52e4db-371e-34e7-92b0-884a5d7c705f/5-of-the-most-hated-biotech-stocks-on-the-market-a.aspx?yptr=yahoo&.tsrc=rss,"Short-sellers have piled on Agios, Insys, Intercept, Lexicon, and Myriad Genetics. But are they wrong?"
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-08-31 12:07:17 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120717478.html?.tsrc=rss,Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  ETFs that hold AGIO had net inflows of $381 million over the last one-month.
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-08-30 12:02:06 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120206421.html?.tsrc=rss,Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  ETFs that hold AGIO had net inflows of $381 million over the last one-month.
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating,2017-08-30 07:00:00 +0000,http://finance.yahoo.com/r/00d42f88-f84c-35a6-b1c4-5a6d20efa46a/agios-pharmaceuticals-shows-rising-price-performance-with-jump-to-92-rs-rating?src=A00220&yptr=yahoo&.tsrc=rss,"Agios Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating."
AGIO,AGIO:UW,BBG004P6MJ59,Biotech Stocks Facing FDA Decision In September,2017-08-29 08:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eLoYmPQkXWM/biotech-stocks-facing-fda-decision-in-september-20170829-00502,Biotech Stocks Facing FDA Decision In September
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : August 28, 2017",2017-08-28 23:53:14 +0000,http://finance.yahoo.com/r/de845b0f-93df-3d2f-974a-f98fdcc11f0c/agios-pharmaceuticals-inc-value-analysis-nasdaqagio-august-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Agios Pharmaceuticals, Inc. a score of 25. Our analysis is based on comparing Agios Pharmaceuticals, Inc. with the following peers – Xencor, Inc., Exelixis, Inc., Pfizer Inc., Eli Lilly and Company, Dare Bioscience, Inc., Alexion Pharmaceuticals, Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR and BioMarin Pharmaceutical Inc. ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,Why You Can Back Up the Truck and Load Up on This Biotech Stock,2017-08-27 14:49:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VOMaFpxhqpc/why-you-can-back-up-the-truck-and-load-up-on-this-biotech-stock-cm837631,Mae West once said Too much of a good thing can be wonderful The late actress wasn t referring to investing but her sentiment is still applicable It makes sense to buy more shares of stocks that present the greatest opportunities Legendary investor Warren Buffett who has
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : August 18, 2017",2017-08-18 13:45:52 +0000,http://finance.yahoo.com/r/08f3f8d4-8ba9-3b2c-a215-4bce6af47f35/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-agio-us-august-18-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Agios Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,Analysts Expect EQWM Will Reach $49,2017-08-16 14:35:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/USlWhoIBnDA/analysts-expect-eqwm-will-reach-49-cm832678,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
AGIO,AGIO:UW,BBG004P6MJ59,Why I Love Celgene Corporation,2017-08-15 13:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nqinhxAJ6js/why-i-love-celgene-corporation-cm832052,Stocks aren t like children It s not a problem at all if you don t love each stock in your investment portfolio equally You can have favorites without even the smallest amount of guilt In my case Celgene Corporation NASDAQ CELG stands out among all the stocks that I own It
AGIO,AGIO:UW,BBG004P6MJ59,See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.,2017-08-14 12:05:19 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120519514.html?.tsrc=rss,"Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  The net inflows of $999,518 over the last one-month into ETFs that hold AGIO are among the lowest of the last year and appear to be slowing."
AGIO,AGIO:UW,BBG004P6MJ59,Edited Transcript of AGIO earnings conference call or presentation 8-Aug-17 12:00pm GMT,2017-08-11 23:01:02 +0000,https://finance.yahoo.com/news/edited-transcript-agio-earnings-conference-161047018.html?.tsrc=rss,Q2 2017 Agios Pharmaceuticals Inc Earnings Call
AGIO,AGIO:UW,BBG004P6MJ59,IHS Markit Score Update: Drop in demand for ETFs holding Agios Pharmaceuticals Inc is a negative sign for its shares,2017-08-10 12:04:13 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120413105.html?.tsrc=rss,Short interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  The net inflows of $244 million over the last one-month into ETFs that hold AGIO are among the lowest of the last year and appear to be slowing.
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y",2017-08-09 17:36:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mb1FATF_nWg/agios-agio-q2-loss-wider-than-expected-revenues-up-yy-cm829621,Agios Pharmaceuticals Inc AGIO posted second quarter 2017 loss of 1 78 per share wider than both the Zacks Consensus Estimate of a loss of 1 52 and the year ago loss of 1 47 Agios shares have significantly outperformed the industry so far this year The company s shares have
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y",2017-08-09 15:13:03 +0000,https://finance.yahoo.com/news/agios-agio-q2-loss-wider-151303991.html?.tsrc=rss,"Agios (AGIO) reports wider-than-expected loss with revenues marginally lagging estimates. However, the top line improves year over year, thanks to reimbursement received from Celgene."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 2Q loss,2017-08-09 02:23:01 +0000,https://finance.yahoo.com/news/agios-pharmaceuticals-reports-2q-loss-114236087.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.78. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss,2017-08-08 15:44:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KkK4e3s_8O4/agios-agio-q2-loss-wider-than-expected-sales-miss-cm828789,Agios Pharmaceuticals Inc AGIO is a development stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders Recently Agios along with its partner Celgene announced that the FDA has granted approval to its lead candidate
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss,2017-08-08 13:12:01 +0000,https://finance.yahoo.com/news/agios-agio-q2-loss-wider-131201799.html?.tsrc=rss,"Agios (AGIO) posted wider-than-expected loss in the second quarter of 2017. Revenues also came below expectations. However, revenues increased significantly year-over-year."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Second Quarter 2017 Financial Results,2017-08-08 11:01:00 +0000,https://finance.yahoo.com/news/agios-reports-second-quarter-2017-110100214.html?.tsrc=rss,–IDHIFA ® Granted Approval from FDA as First Targeted Therapy for Patients with IDH2m R/R AML and First Product Approved from Agios’ Discovery Platform–. –Trial Designs Finalized for Two Pivotal Studies ...
AGIO,AGIO:UW,BBG004P6MJ59,4 Medical Product Stocks Likely to Top Q2 Earnings Estimates,2017-08-07 20:35:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iDTZuTjyB4U/4-medical-product-stocks-likely-to-top-q2-earnings-estimates-cm828321,The political gridlock over the Affordable Care Act or Obamacare has been making headlines in the MedTech space Amid such political conundrum at the Capitol Hill market watchers will be keeping a tab on the MedTech space Of the recent developments the GOP failure at Senate to
AGIO,AGIO:UW,BBG004P6MJ59,4 Medical Product Stocks Likely to Top Q2 Earnings Estimates,2017-08-07 18:50:06 +0000,https://finance.yahoo.com/news/4-medical-product-stocks-likely-185006128.html?.tsrc=rss,There are some powerful long-term tailwinds in the medical space.
AGIO,AGIO:UW,BBG004P6MJ59,"Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More",2017-08-07 15:42:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xiyp8_RO5jw/med-product-stocks-aug-8-earnings-roster-hsic-agio-more-cm828085,We are at the last lap of Q2 earnings season and per the Earnings Preview till Aug 4 around 420 S amp P 500 members 86 7 of the Index s total market cap have reported their quarterly numbers Putting together these results we can see that the pace of earnings and revenue growth is
AGIO,AGIO:UW,BBG004P6MJ59,Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?,2017-08-07 14:41:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zxnCN0U-yzQ/is-a-surprise-coming-for-agios-pharmaceuticals-agio-this-earnings-season-cm828015,Investors are always looking for stocks that are poised to beat at earnings season and Agios Pharmaceuticals Inc AGIO may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Agios Pharmaceuticals
AGIO,AGIO:UW,BBG004P6MJ59,"Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More",2017-08-07 13:34:01 +0000,https://finance.yahoo.com/news/med-product-stocks-aug-8-133401746.html?.tsrc=rss,"Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry."
AGIO,AGIO:UW,BBG004P6MJ59,Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season?,2017-08-07 12:43:12 +0000,https://finance.yahoo.com/news/surprise-coming-agios-pharmaceuticals-agio-124312788.html?.tsrc=rss,Agios Pharmaceuticals (AGIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AGIO,AGIO:UW,BBG004P6MJ59,Will Expenses Hit Envision Healthcare (EVHC) Q2 Earnings?,2017-08-04 16:04:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/roXIwfSxw0Y/will-expenses-hit-envision-healthcare-evhc-q2-earnings-cm827250,Envision Healthcare Corp EVHC is scheduled to report second quarter 2017 results on Aug 7 after market close Last quarter this health services company performed in line with the Zacks Consensus Estimate However earnings declined 6 8 year over year due to an increase in expense
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017",2017-08-03 20:01:00 +0000,https://finance.yahoo.com/news/agios-present-canaccord-genuity-37th-200100899.html?.tsrc=rss,"CAMBRIDGE, Mass., Aug. 03, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Reaches Analyst Target Price,2017-08-03 15:01:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ooO5A-0Hkx0/agios-pharmaceuticals-reaches-analyst-target-price-cm826376,In recent trading shares of Agios Pharmaceuticals Inc Symbol AGIO have crossed above the average analyst 12 month target price of 61 00 changing hands for 61 64 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session,2017-08-03 14:03:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NsVQO0vXnhY/agios-pharmaceuticals-agio-looks-good-stock-adds-51-in-session-cm826440,Agios Pharmaceuticals Inc AGIO was a big mover last session as the company saw its shares rise over 5 on the day The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up 18 13
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session,2017-08-03 12:36:12 +0000,https://finance.yahoo.com/news/agios-pharmaceuticals-agio-looks-good-123612851.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise over 5% on the day."
AGIO,AGIO:UW,BBG004P6MJ59,Celgene CEO: Precision medicine targeting metabolic drive...,2017-08-03 12:15:00 +0000,https://finance.yahoo.com/video/celgene-ceo-precision-medicine-targeting-121500066.html?.tsrc=rss,"Mark Alles, Celgene CEO, talks about gaining FDA approval for a drug that targets a lethal form of leukemia and discusses the importance of getting patients access to precision medicines."
AGIO,AGIO:UW,BBG004P6MJ59,3 Reasons the Best Is Yet to Come for Celgene,2017-08-03 02:54:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T88UgkLb6BU/3-reasons-the-best-is-yet-to-come-for-celgene-cm826180,Celgene Corp s NASDAQ CELG second quarter revenue and sales came in nearly 50 higher than they were two short years ago yet the company doesn t appear to be anywhere near peaking A flurry of R amp D activity should provide it with a steady stream of label expansion and new
AGIO,AGIO:UW,BBG004P6MJ59,"Gainers & Losers Of Aug.2: ONCE, ILMN, XENT, NOVN, FLKS...",2017-08-02 22:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9F0Ot6PnVn8/gainers--losers-of-aug2-once-ilmn-xent-novn-flks-20170802-02061,"Gainers & Losers Of Aug.2: ONCE, ILMN, XENT, NOVN, FLKS..."
AGIO,AGIO:UW,BBG004P6MJ59,This Small Biotech Launched To A 9-Month High Today — Here&apos;s Why,2017-08-02 20:07:58 +0000,http://finance.yahoo.com/r/697b0ec3-080c-3fcd-8d0c-1dccfaf17062/this-small-biotech-launched-to-a-9-month-high-today-heres-why?src=A00220&yptr=yahoo&.tsrc=rss,Agios launched to a nine-month high Wednesday after the FDA approved its blood cancer drug — a development that bodes well for a similar medicine in its pipeline.
AGIO,AGIO:UW,BBG004P6MJ59,"Biotech Stock Roundup: Q2 Earnings from Gilead, CELG & More, Dynavax Up on Panel Vote",2017-08-02 13:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ygn6jRG4Qg4/biotech-stock-roundup-q2-earnings-from-gilead-celg-more-dynavax-up-on-panel-vote-cm825704,Major biotech stocks like Gilead GILD Celgene CELG Alexion AbbVie ABBV and Vertex VRTX reported second quarter results over the last few days Companies like Gilead and Amgen AMGN also provided regulatory updates 160 Recap of the Week s Most Important Stories A Look at
AGIO,AGIO:UW,BBG004P6MJ59,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount",2017-08-02 02:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NKjz_8xnheE/fda-nod-for-agios-idhifa-bmy-expands-opdivo-use-ocul-reduces-headcount-20170802-00079,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount"
AGIO,AGIO:UW,BBG004P6MJ59,FDA Oks New Targeted Treatment For Relapsed Or Refractory Acute Myeloid Leukemia,2017-08-01 21:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WzVhhWRVLzk/fda-oks-new-targeted-treatment-for-relapsed-or-refractory-acute-myeloid-leukemia-20170801-01942,FDA Oks New Targeted Treatment For Relapsed Or Refractory Acute Myeloid Leukemia
AGIO,AGIO:UW,BBG004P6MJ59,"FDA approves leukemia treatment developed by Celgene, Agios",2017-08-01 19:06:41 +0000,https://finance.yahoo.com/news/fda-approves-leukemia-treatment-developed-160624424.html?.tsrc=rss,"The U.S. Food and Drug Administration  (FDA) on Tuesday approved Celgene Corp and Agios  Pharmaceuticals Inc's oral treatment for acute myeloid  leukemia (AML) patients with a rare genetic mutation.  The drug, Idhifa, will have a monthly list price of $24,872,  Celgene said in an email, noting that the median time on therapy  for patients was 4.3 months in the trial to secure the FDA's  approval."
AGIO,AGIO:UW,BBG004P6MJ59,A small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved,2017-08-01 15:47:46 +0000,https://finance.yahoo.com/news/small-biotech-behind-groundbreaking-approach-154746987.html?.tsrc=rss,"Agios Pharmaceuticals, a company that got its start less than a decade ago, just got its first..."
AGIO,AGIO:UW,BBG004P6MJ59,"FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation",2017-08-01 15:30:00 +0000,https://finance.yahoo.com/news/fda-grants-approval-idhifa-first-153000126.html?.tsrc=rss,"Celgene Corporation and Agios Pharmaceuticals, Inc. today announced that IDHIFA® was granted approval from the U.S. Food and Drug Administr"
AGIO,AGIO:UW,BBG004P6MJ59,Key FDA Events to Watch Out for in Aug 2017,2017-08-01 12:57:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fYPlKUCJw4M/key-fda-events-to-watch-out-for-in-aug-2017-cm824807,The FDA which approved 22 treatments last year has given its approval to 26 drugs so far in 2017 including 3 in July Key approvals this year include Gilead s Vosevi hepatitis C virus Puma s Nerlynx to reduce the risk of breast cancer returning J amp J s Tremfya moderate to severe
AGIO,AGIO:UW,BBG004P6MJ59,Biotech Stocks Facing FDA Decision In August,2017-07-31 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6SiGP_nfTo/biotech-stocks-facing-fda-decision-in-august-20170731-00044,Biotech Stocks Facing FDA Decision In August
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017",2017-07-28 11:30:00 +0000,https://finance.yahoo.com/news/agios-webcast-conference-call-second-113000741.html?.tsrc=rss,"CAMBRIDGE, Mass., July 28, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View",2017-07-27 17:58:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EWmGOLf8H4g/celgene-celg-beats-q2-earnings-sales-estimates-ups-view-cm822690,Celgene Corporation CELG reported second quarter 2017 earnings of 1 68 per share including share based compensation expense and tax adjustments beating the Zacks Consensus Estimate of 1 61 and up from 1 28 per share in the year ago quarter Celgene s share price movement shows
AGIO,AGIO:UW,BBG004P6MJ59,Revlimid drives Celgene profit beat; raises EPS forecast,2017-07-27 15:37:51 +0000,https://finance.yahoo.com/news/celgene-beats-profit-estimates-raises-121040339.html?.tsrc=rss,Celgene Corp rode its flagship  multiple myeloma drug Revlimid and a rebound in sales of Otezla  for psoriasis to a modestly higher-than-expected second-quarter  profit and raised its full-year earnings forecast on Thursday.  Analysts said the results may have come up short of  investors' lofty expectations for Celgene.  Revlimid sales rose 19.6 percent to $2.03 billion on  increases in duration of use and new reimbursement agreements in  Europe.
AGIO,AGIO:UW,BBG004P6MJ59,"Commit To Purchase Agios Pharmaceuticals At $45, Earn 10.9% Annualized Using Options",2017-07-26 17:00:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3kSCcCGwCtQ/commit-to-purchase-agios-pharmaceuticals-at-45-earn-109-annualized-using-options-cm821833,Investors considering a purchase of Agios Pharmaceuticals Inc Symbol AGIO stock but cautious about paying the going market price of 58 44 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
AGIO,AGIO:UW,BBG004P6MJ59,What's in Store for Agios Pharma (AGIO) in Q2 Earnings?,2017-07-26 16:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7TpzKkKYO34/whats-in-store-for-agios-pharma-agio-in-q2-earnings-cm821810,Agios Pharmaceuticals Inc AGIO is expected to report second quarter results on Aug 3 Shares have surged 38 9 so far this year comparing favorably with the 160 industry s increase of 22 3 Agios performance has been mixed with the company missing estimates twice in the
AGIO,AGIO:UW,BBG004P6MJ59,What&apos;s in Store for Agios Pharma (AGIO) in Q2 Earnings?,2017-07-26 14:55:02 +0000,https://finance.yahoo.com/news/apos-store-agios-pharma-agio-145502644.html?.tsrc=rss,"Encouraging performance of Agios&apos; (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2."
AGIO,AGIO:UW,BBG004P6MJ59,Is Celgene (CELG) Poised For a Beat This Earnings Season?,2017-07-24 16:09:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xNhWO-IuSHA/is-celgene-celg-poised-for-a-beat-this-earnings-season-cm820167,Celgene Corporation CELG is scheduled to report second quarter 2017 results on Jul 27 before the opening bell Last quarter the company beat expectations by 4 08 Celgene has outperformed the Zacksclassified industry in the year so far The stock has gained 19 during this
AGIO,AGIO:UW,BBG004P6MJ59,Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO,2017-07-12 18:56:00 +0000,https://finance.yahoo.com/news/newman-ferrara-llp-announces-corporate-185600916.html?.tsrc=rss,Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
AGIO,AGIO:UW,BBG004P6MJ59,"Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China",2017-07-06 22:45:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/39s_HzG0JKw/celgene-celg-beigene-team-up-for-pd-1-inhibitor-in-china-cm812738,Celgene Corporation CELG recently entered into a strategic collaboration with China based BeiGene Ltd BGNE Per the deal Celgene will develop and commercialize BeiGene s investigational anti programmed cell death protein 1 PD 1 inhibitor BGB A317 The candidate will be used to
AGIO,AGIO:UW,BBG004P6MJ59,Agios/Celgene's Leukemia Candidate Positive in Phase I/II,2017-06-27 17:50:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q8vazVjtzDA/agioscelgenes-leukemia-candidate-positive-in-phase-iii-cm808933,Agios Pharmaceuticals Inc AGIO has announced positive efficacy and safety data from the ongoing phase I II dose escalation and expansion study on experimental candidate IDHIFA enasidenib at an oral session at the European Hematology Association EHA IDHIFA is being developed for
AGIO,AGIO:UW,BBG004P6MJ59,Agios/Celgene&apos;s Leukemia Candidate Positive in Phase I/II,2017-06-27 15:38:03 +0000,https://finance.yahoo.com/news/agios-celgene-apos-leukemia-candidate-153803237.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA)."
AGIO,AGIO:UW,BBG004P6MJ59,Biotech Rally Stumbles As These Small Caps Pull Back,2017-06-26 20:10:29 +0000,http://finance.yahoo.com/r/b1b5d241-6fbd-30fa-a171-a557b73d86dd/biotech-rally-stumbles-as-these-small-caps-pull-back?src=A00220&yptr=yahoo&.tsrc=rss,"Agios stock toppled Monday, two days after the biotech unveiled disappointing data for its drug, enasidenib, in patients with a blood cancer."
AGIO,AGIO:UW,BBG004P6MJ59,Agio Pharma Sinks on Midstage Trial,2017-06-26 15:05:35 +0000,https://finance.yahoo.com/news/agio-pharma-sinks-midstage-trial-150535301.html?.tsrc=rss,Agio Pharmaceuticals saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia.
AGIO,AGIO:UW,BBG004P6MJ59,InPlay from Briefing.com,2017-06-26 06:57:35 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017,2017-06-24 20:54:05 +0000,https://finance.yahoo.com/news/agios-pharma-announces-updated-data-205405905.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) presented updated data from its wholly owned pyruvate kinase-R (PKR) activator demonstrating the potential for the first disease-modifying treatment for patients ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Updated Data From AG-348 Trial - Quick Facts,2017-06-24 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4BWwtCK1iw8/agios-reports-updated-data-from-ag348-trial--quick-facts-20170624-00010,Agios Reports Updated Data From AG-348 Trial - Quick Facts
AGIO,AGIO:UW,BBG004P6MJ59,New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML,2017-06-24 12:05:00 +0000,https://finance.yahoo.com/news/data-phase-1-2-trial-120500399.html?.tsrc=rss,Inclusion of Phase 2 Expansion Data Demonstrates Overall Efficacy and Safety Profile Consistent with Previously Reported Data. In 214 R/R AML Patients Treated with Enasidenib at 100 mg Daily Dose in Phase ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency,2017-06-24 12:00:00 +0000,https://finance.yahoo.com/news/agios-announces-updated-data-fully-120000454.html?.tsrc=rss,"–AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin Increases in 25 of 52 Patients Overall–. –New Data Show Improvements in Hemolysis Associated Parameters Indicate ..."
AGIO,AGIO:UW,BBG004P6MJ59,Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial,2017-06-16 00:06:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BByQyNFvC0A/celgene-celg-reports-data-on-lupus-drug-in-phase-ii-trial-cm804154,Celgene Corporation CELG announced results from the phase II trial SLE 001 at the Annual European Congress of Rheumatology EULAR 2017 in Madrid The trial evaluated investigational candidate CC 220 The data showed greater improvement with CC 220 an oral immunomodulatory compound
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : June 15, 2017",2017-06-15 16:57:17 +0000,http://finance.yahoo.com/r/f671ef0c-52a8-347d-afd1-eda4ea93f57f/etfs-with-exposure-to-agios-pharmaceuticals-inc-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : June 14, 2017",2017-06-14 17:58:19 +0000,http://finance.yahoo.com/r/a51ee920-f221-380e-b88f-77150b2000f6/agios-pharmaceuticals-inc-value-analysis-nasdaqagio-june-14-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Agios Pharmaceuticals, Inc. a score of 25. Our analysis is based on comparing Agios Pharmaceuticals, Inc. with the following peers – Xencor, Inc., Exelixis, Inc., Pfizer Inc., Eli Lilly and Company, Cerulean Pharma, Inc., Alexion Pharmaceuticals, Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR and BioMarin Pharmaceutical Inc. ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : June 13, 2017",2017-06-13 12:26:54 +0000,http://finance.yahoo.com/r/cf7535a2-97ce-3bbf-8d62-612e5ccd5f60/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-agio-us-june-13-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Agios Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue?,2017-06-08 09:28:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6WfpnbmNgjE/agios-agio-up-26-since-earnings-report-can-it-continue-cm800363,A month has gone by since the last earnings report for Agios Pharmaceuticals Inc AGIO Shares have added about 2 6 in the past month outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before we
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue?,2017-06-08 07:32:07 +0000,https://finance.yahoo.com/news/agios-agio-2-6-since-073207711.html?.tsrc=rss,Agios (AGIO) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
AGIO,AGIO:UW,BBG004P6MJ59,Celgene and Agios Announce Data on Idhifa for Leukemia,2017-06-07 15:29:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5XZZWfVxQeg/celgene-and-agios-announce-data-on-idhifa-for-leukemia-cm800067,Celgene Corporation CELG and partner Agios Pharmaceuticals Inc AGIO announced new efficacy and safety data from the ongoing phase I dose escalation and expansion study on experimental candidate Idhifa enasidenib at an oral session at the American Society of Clinical Oncology ASCO
AGIO,AGIO:UW,BBG004P6MJ59,Celgene and Agios Announce Data on Idhifa for Leukemia,2017-06-07 14:07:02 +0000,https://finance.yahoo.com/news/celgene-agios-announce-data-idhifa-140702653.html?.tsrc=rss,"Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib)."
AGIO,AGIO:UW,BBG004P6MJ59,Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation,2017-06-06 16:26:00 +0000,https://finance.yahoo.com/news/updated-data-phase-1-trial-162600034.html?.tsrc=rss,"Celgene Corporation and Agios Pharmaceuticals, Inc. today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral IDHIFA® in patients with relapsed or refractory acute myeloid leukemia and an isocitrate dehydrogenase-2 mutation."
AGIO,AGIO:UW,BBG004P6MJ59,"Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data",2017-06-05 17:48:02 +0000,https://finance.yahoo.com/news/notes-asco-2017-tesaro-amgen-174802731.html?.tsrc=rss,The 2017 American Society of Clinical Oncology annual meeting is taking place in Chicago from last Friday through Tuesday. There have already been several companies that have updated shareholders with ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma,2017-06-03 13:00:00 +0000,https://finance.yahoo.com/news/agios-presents-phase-1-data-130000535.html?.tsrc=rss,Durable Disease Control with Six Month PFS rate of 38.5% and 12 Month PFS Rate of 20.7%; Median PFS of 3.8 Months. Stable Disease Observed in 56% of Patients; 5% of Patients Achieved a Partial Response. ...
AGIO,AGIO:UW,BBG004P6MJ59,Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review,2017-06-01 17:32:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WUUSCLE-ocs/jazz-pharmaceuticals-vyxeos-nda-granted-priority-review-cm797548,Jazz Pharmaceuticals plc JAZZ announced that the New Drug Application NDA for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA The specialty biopharmaceutical company is looking to get Vyxeos cytarabine and daunorubicin liposome injection
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Appoints David Scadden, M.D., to the Board of Directors",2017-05-31 20:05:00 +0000,https://finance.yahoo.com/news/agios-appoints-david-scadden-m-200500637.html?.tsrc=rss,"CAMBRIDGE, Mass., May 31, 2017-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic diseases, today announced the appointment of David Scadden, M.D., to its board ..."
AGIO,AGIO:UW,BBG004P6MJ59,The Math Shows IYH Can Go To $175,2017-05-30 14:31:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWhe8PztuBE/the-math-shows-iyh-can-go-to-175-cm796082,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : May 22, 2017",2017-05-22 17:19:44 +0000,http://finance.yahoo.com/r/c89997ef-863b-3261-b99d-adeb4096f7a4/etfs-with-exposure-to-agios-pharmaceuticals-inc-may-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,A small Boston biotech is at the heart of a groundbreaking approach to tackling cancer,2017-05-21 17:00:00 +0000,https://finance.yahoo.com/news/small-boston-biotech-heart-groundbreaking-170000200.html?.tsrc=rss,"Agios Pharmaceuticals, a company that got its start less than a decade ago, already has one drug..."
AGIO,AGIO:UW,BBG004P6MJ59,3 Stocks To Buy When The Market's Crashing,2017-05-18 18:13:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j1Fmir-rBu0/3-stocks-to-buy-when-the-markets-crashing-cm791406,Stocks don t go up or down in a straight line So with shares flirting with new highs a drop isn t unexpected As markets fall buying shares in fast growing companies on sale could lead to market beating performance when markets return to their winning ways Three of my
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA,2017-05-18 11:08:17 +0000,https://finance.yahoo.com/news/agios-present-updated-clinical-data-110817244.html?.tsrc=rss,"CAMBRIDGE, Mass., May 18, 2017-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic diseases, today announced that updated clinical data from the fully enrolled, ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Present New Clinical Data from its IDH Programs at ASCO,2017-05-17 21:29:59 +0000,https://finance.yahoo.com/news/agios-present-clinical-data-idh-212959975.html?.tsrc=rss,–Updated Data from IDHIFA ® Phase 1 Trial in IDH2m R/R AML to be Presented in Oral Presentation; Abstract Selected for Best of ASCO Program–. –First Data from the Ivosidenib Phase 1 Cholangiocarcinoma ...
AGIO,AGIO:UW,BBG004P6MJ59,"Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract",2017-05-17 21:02:00 +0000,http://finance.yahoo.com/r/50aaaa92-f6da-3cc2-830f-a717c0e165a0/celgene-agios-update-blood-cancer-drug-study-results-in-asco-17-abstract.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : May 15, 2017",2017-05-15 12:20:21 +0000,http://finance.yahoo.com/r/db67ffcc-3796-30d6-99fc-43a1035edd53/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-agio-us-may-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Agios Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,Edited Transcript of AGIO earnings conference call or presentation 4-May-17 12:00pm GMT,2017-05-12 15:15:59 +0000,http://finance.yahoo.com/news/edited-transcript-agio-earnings-conference-071236905.html?.tsrc=rss,Q1 2017 Agios Pharmaceuticals Inc Earnings Call
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : May 8, 2017",2017-05-08 20:06:13 +0000,http://finance.yahoo.com/r/d0a626fb-9615-3976-a7fe-828093a16ca6/etfs-with-exposure-to-agios-pharmaceuticals-inc-may-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Agios Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AGIO-US. Comparing the performance and risk of Agios Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus",2017-05-05 15:27:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PGjFe-CjgWU/agios-agio-q1-loss-narrower-than-expected-indhifa-in-focus-cm785031,Agios Pharmaceuticals Inc AGIO posted first quarter 2017 loss of 1 56 per share narrower than the Zacks Consensus Estimate of a loss of 1 79 but wider than the year ago loss of 61 cents Agios s shares have underperformed the Zacks classified Medical Products industry so far
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017",2017-05-05 15:10:08 +0000,http://finance.yahoo.com/r/df324e0e-3e6e-3ae5-ac7c-bd7a76cf72b9/agios-pharmaceuticals-inc-agio-us-earnings-analysis-q1-2017-by-the-numbers-may-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Agios Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Agios Pharmaceuticals, Inc. – Exelixis, Inc., Pfizer Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Celgene Corporation and GlaxoSmithKline plc Sponsored ADR (EXEL-US, PFE-US, LLY-US, ALXN-US, CELG-US and ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus",2017-05-05 14:04:02 +0000,http://finance.yahoo.com/news/agios-agio-q1-loss-narrower-140402173.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents."
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y,2017-05-04 14:14:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jtq-nm3ZCb4/agios-agio-q1-loss-narrower-than-expected-sales-down-yy-cm784146,Agios Pharmaceuticals Inc AGIO is a development stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders The company has several interesting candidates in its pipeline Its cancer pipeline comprises enasidenib IDH2
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y,2017-05-04 13:14:01 +0000,http://finance.yahoo.com/news/agios-agio-q1-loss-narrower-131401310.html?.tsrc=rss,"Agios posted narrower-than-expected loss in the first quarter of 2017. Our consensus called for a loss of $1.79 per share, and the company reported a loss of $1.56."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 1Q loss,2017-05-04 12:01:39 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-reports-1q-loss-120139352.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.56. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Investor Network: Agios Pharmaceuticals, Inc. to Host Earnings Call",2017-05-04 11:05:00 +0000,http://finance.yahoo.com/news/investor-network-agios-pharmaceuticals-inc-110500909.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 4, 2017 / Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) will be discussing their earnings results in their Q1 Earnings Call to be held May 4, 2017 at 8:00 AM Eastern Time. ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports First Quarter 2017 Financial Results,2017-05-04 11:01:00 +0000,http://finance.yahoo.com/news/agios-reports-first-quarter-2017-110100516.html?.tsrc=rss,"–IDHIFA ® Granted Priority Review by FDA with August 30, 2017 PDUFA Date; Updated Data from Phase 1/ 2 Trial in IDH2m R/R AML to be Presented at ASCO–. –Ivosidenib Phase 1 125- Patient Expansion Cohort ..."
AGIO,AGIO:UW,BBG004P6MJ59,3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash,2017-05-03 12:27:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-z1pkrH_AtU/3-debt-free-clinical-stage-biotech-stocks-that-are-swimming-in-cash-cm783215,Investing in biotech stocks is like playing roulette in a casino The odds are clearly against you with most discovery stage preclinical and clinical stage experimental drugs failing to meet their trial goals However if a drug or multiple drugs within a pipeline do succeed
AGIO,AGIO:UW,BBG004P6MJ59,3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash,2017-05-03 11:18:00 +0000,http://finance.yahoo.com/r/645b830f-6896-30c5-9b65-222e83280d7e/3-debt-free-clinical-stage-biotech-stocks-that-are.aspx?yptr=yahoo&.tsrc=rss,Funding isn&apos;t a big concern for these three drug developers.
AGIO,AGIO:UW,BBG004P6MJ59,[$$] Four Small Biotechs See Bullish April Stock Buys,2017-05-03 09:51:00 +0000,http://finance.yahoo.com/r/48412691-f35c-31d5-b2a8-feaea1418814/four-small-biotechs-see-bullish-april-stock-buys-1493805107?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Surfing is an apt comparison with biotech investing when considering the gnarly spellings of drug developers and medicines, the importance of having good pipelines, and what a wipeout the sector was last year.  After catching waves of double-digit returns from 2012 through 2015, the S&P Biotechnology Select Industry index crashed 16% in 2016.  For the investor who is looking for individual picks rather than a sector exchange-traded fund (the SPDR S&P Biotech ETF (XBI) tracks the index while the Direxion Daily S&P Biotech Bear 1X Shares (LABS) bets against it by seeking an inverse return), some bullish buys in April of Agios Pharmaceuticals (AGIO), BioLine Rx (BLRX), Tocagen (TOCA) and OncoMed Pharmaceuticals (OMED) may be of interest."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?,2017-05-01 16:31:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UEE1oOnqS3o/agios-pharmaceuticals-agio-q1-earnings-whats-in-store-cm782059,Agios Pharmaceuticals Inc AGIO is scheduled to report first quarter results on May 4 before market open Shares gained 19 1 so far this year while the Zacks classified Medical Products industry witnessed an increase of 14 3 Agios performance has been mixed with the company
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Q1 Earnings: What&apos;s in Store?,2017-05-01 14:21:02 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-agio-q1-earnings-142102657.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Closing of Over-Allotment Option in Public Offering,2017-04-28 20:01:00 +0000,http://finance.yahoo.com/news/agios-announces-closing-over-allotment-200100541.html?.tsrc=rss,"CAMBRIDGE, Mass., April 28, 2017-- Agios Pharmaceuticals, Inc. today announced that it has issued an additional 757,575 shares of common stock at the public offering price of $49.50 per share, for total ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View",2017-04-27 17:31:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k30rc6ns-qs/celgene-celg-tops-on-q1-earnings-sales-miss-raises-view-cm780499,Celgene Corporatio n CELG reported first quarter 2017 earnings of 1 53 per share including share based compensation expense and tax adjustments beating the Zacks Consensus Estimate of 1 47 but up from 1 18 per share in the year ago quarter Celgene s share price movement shows
AGIO,AGIO:UW,BBG004P6MJ59,Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target,2017-04-27 11:30:00 +0000,http://finance.yahoo.com/news/agios-aurigene-enter-exclusive-license-113000140.html?.tsrc=rss,"CAMBRIDGE, Mass., April 27, 2017-- Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017",2017-04-27 11:25:00 +0000,http://finance.yahoo.com/news/agios-webcast-conference-call-first-112500303.html?.tsrc=rss,"CAMBRIDGE, Mass., April 27, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference ..."
AGIO,AGIO:UW,BBG004P6MJ59,The 1 Stock I'd Buy Right Now,2017-04-26 14:05:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k8FYvHcFIg4/the-1-stock-id-buy-right-now-cm779302,There are more than 5 700 publicly traded companies in the U S Even more are listed on non U S stock exchanges Investors definitely have plenty of options If you could only buy one stock though which would it be It s a very tough decision because there are quite a few
AGIO,AGIO:UW,BBG004P6MJ59,The 1 Stock I&apos;d Buy Right Now,2017-04-26 12:04:00 +0000,http://finance.yahoo.com/r/48da4947-94f2-342d-a45e-03970616a9f5/the-1-stock-id-buy-right-now.aspx?yptr=yahoo&.tsrc=rss,"In the vast ocean of stocks, big biotech Celgene is the one that looks most attractive to me at the moment."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Exercise of Over-Allotment Option in Public Offering,2017-04-26 11:01:00 +0000,http://finance.yahoo.com/news/agios-announces-exercise-over-allotment-110100485.html?.tsrc=rss,"CAMBRIDGE, Mass., April 26, 2017-- Agios Pharmaceuticals, Inc. today announced that the underwriters of its previously announced public offering of common stock have fully exercised their option to purchase ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Commit To Buy Agios Pharmaceuticals At $35, Earn 9.4% Annualized Using Options",2017-04-25 17:03:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_m7TZlZvQVk/commit-to-buy-agios-pharmaceuticals-at-35-earn-94-annualized-using-options-cm778773,Investors eyeing a purchase of Agios Pharmaceuticals Inc Symbol AGIO shares but cautious about paying the going market price of 48 79 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
AGIO,AGIO:UW,BBG004P6MJ59,Liberty Sirius XM Group (LSXMK) Lead 12 Activist Investor Reports,2017-04-25 17:02:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gRbA8K8x8Lg/liberty-sirius-xm-group-lsxmk-lead-12-activist-investor-reports-cm778885,InvestorPlace Stock Market News Stock Advice amp Trading Tips When a person or group of persons acquires beneficial ownership of more than 5 of a company s equity securities they are required to file a Schedule 13D or 13G with the SEC If these groups intend
AGIO,AGIO:UW,BBG004P6MJ59,Key Factors to Look Out for in Celgene's (CELG) Q1 Results,2017-04-25 14:08:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UsVLGeMUSN0/key-factors-to-look-out-for-in-celgenes-celg-q1-results-cm778639,Earnings season for the pharma and biotech sector will start in full flow this week with several major companies scheduled to report results Celgene Corporation CELG is one of the companies that will be reporting results later this week A look at the company s earnings track record
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Closing of Public Offering,2017-04-24 20:01:00 +0000,http://finance.yahoo.com/news/agios-announces-closing-public-offering-200100108.html?.tsrc=rss,"CAMBRIDGE, Mass., April 24, 2017-- Agios Pharmaceuticals, Inc. today announced the closing of its previously announced underwritten public offering of 5,050,505 shares common stock at the public offering ..."
AGIO,AGIO:UW,BBG004P6MJ59,9 Reasons Celgene Could Be the World's Most Perfect Stock,2017-04-24 14:05:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HKY73jixTes/9-reasons-celgene-could-be-the-worlds-most-perfect-stock-cm777736,The average investor has more than 5 000 publicly traded stocks on reputable U S exchanges to choose from With that much hay in the barn finding that needle can be quite difficult But if you re looking for the world s most perfect stock perhaps your search might end with
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : April 20, 2017",2017-04-20 18:47:00 +0000,http://finance.yahoo.com/r/8cda0894-d9a2-3bba-a313-8b6650857b0c/agios-pharmaceuticals-inc-value-analysis-nasdaqagio-april-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Agios Pharmaceuticals, Inc. a score of 25. Our analysis is based on comparing Agios Pharmaceuticals, Inc. with the following peers – Xencor, Inc., Exelixis, Inc., Pfizer Inc., Eli Lilly and Company, Cerulean Pharma, Inc., Alexion Pharmaceuticals, Inc., Celgene Corporation, GlaxoSmithKline plc Sponsored ADR and BioMarin Pharmaceutical Inc. ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : April 19, 2017",2017-04-19 12:30:34 +0000,http://finance.yahoo.com/r/68a8d536-8b3a-343e-9977-2a7049f3d3d9/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-agio-us-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Agios Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,InPlay from Briefing.com,2017-04-19 07:56:39 +0000,http://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Pricing of $250 Million Public Offering of Common Stock,2017-04-19 00:34:36 +0000,http://finance.yahoo.com/news/agios-announces-pricing-250-million-003436702.html?.tsrc=rss,"CAMBRIDGE, Mass., April 18, 2017-- Agios Pharmaceuticals, Inc. today announced that it has priced an underwritten a public offering of 5,050,505 shares of common stock at a price to the public of $49.50 ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Gainers & Losers Of Apr.18: XOMA, AKTX, CYTK, AGIO, SRNE...",2017-04-18 23:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Sn1BezMIe24/gainers--losers-of-apr18-xoma-aktx-cytk-agio-srne-20170418-01500,"Gainers & Losers Of Apr.18: XOMA, AKTX, CYTK, AGIO, SRNE..."
AGIO,AGIO:UW,BBG004P6MJ59,"Tuesday's ETF Movers: ITB, FBT",2017-04-18 20:03:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lbiB_4VUacY/tuesdays-etf-movers-itb-fbt-cm775468,In trading on Tuesday the iShares U S Home Construction ETF ITB is outperforming other ETFs up about 0 7 on the day Components of that ETF showing particular strength include shares of Tile Shop Holdings TTS up about 7 9 and shares of Beazer Homes USA BZH up about 4 9 on
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Proposed Offering of Common Stock,2017-04-17 20:01:00 +0000,http://finance.yahoo.com/news/agios-announces-proposed-offering-common-200100772.html?.tsrc=rss,"CAMBRIDGE, Mass., April 17, 2017-- Agios Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, up to 4.5 million shares of its common stock in an underwritten ..."
AGIO,AGIO:UW,BBG004P6MJ59,3 Cancer Drug Stocks That Could Make You Rich,2017-04-17 13:57:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xpDwbhshm1w/3-cancer-drug-stocks-that-could-make-you-rich-cm774471,There are more promising cancer treatments in development now than at any other point in human history That s great news for cancer patients It s also good news for investors looking for stocks with significant potential Three cancer drug stocks in particular could be huge winners
AGIO,AGIO:UW,BBG004P6MJ59,3 Cancer Drug Stocks That Could Make You Rich,2017-04-17 12:42:00 +0000,http://finance.yahoo.com/r/459e81e5-f459-3d2c-b8af-96a2ec5bb4eb/3-cancer-drug-stocks-that-could-make-you-rich.aspx?yptr=yahoo&.tsrc=rss,"Agios, Celldex, and Clovis stand out as cancer drug stocks that could generate big returns."
AGIO,AGIO:UW,BBG004P6MJ59,3 Rock-Solid Stocks to Buy Before the Next Market Crash,2017-04-13 14:58:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5uZkGOrWp9U/3-rock-solid-stocks-to-buy-before-the-next-market-crash-cm773736,The S amp P 500 is up more than 200 since the end of 2008 and the bull market is now the second longest on record With stocks flirting with new highs daily it s reasonable to expect a pull back at some point and if so then our Motley Fool contributors think you ll want to
AGIO,AGIO:UW,BBG004P6MJ59,3 Perfect Stocks You Can Buy Now,2017-04-07 14:57:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_PF24UxQCd4/3-perfect-stocks-you-can-buy-now-cm771316,Rapid top and bottom line growth bullet proof balance sheets and innovation first management teams make Amazon com NASDAQ AMZN Facebook NASDAQ FB and Celgene Corp NASDAQ CELG incredibly intriguing stocks to buy in portfolios A forest of
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017",2017-03-30 11:30:00 +0000,http://finance.yahoo.com/news/agios-present-16th-annual-needham-113000472.html?.tsrc=rss,"CAMBRIDGE, Mass., March 30, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017",2017-03-30 11:30:00 +0000,http://finance.yahoo.com/news/agios-present-16th-annual-needham-113000472.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 30, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,Analysts Anticipate FBT Will Reach $122,2017-03-23 13:59:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIdDWnxk6RM/analysts-anticipate-fbt-will-reach-122-cm764591,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
AGIO,AGIO:UW,BBG004P6MJ59,"4 Health Care Charts Signaling Buys: Pfizer, Amgen Included",2017-03-21 16:49:00 +0000,https://www.thestreet.com/story/14052305/1/4-health-care-charts-signaling-buys-pfizer-amgen-included.html?puc=yahoo&cm_ven=YAHOO,"4 Health Care Charts Signaling Buys: Pfizer, Amgen Included"
AGIO,AGIO:UW,BBG004P6MJ59,"4 Health Care Charts Signaling Buys: Pfizer, Amgen Included",2017-03-21 16:49:00 +0000,http://finance.yahoo.com/r/bed8538f-bca8-3889-9837-8706056b01fb/4-health-care-charts-signaling-buys-pfizer-amgen-included.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Obamacare? Trumpcare? These stocks don't care.
AGIO,AGIO:UW,BBG004P6MJ59,"Monday's ETF Movers: FBT, XRT",2017-03-20 19:07:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yuF9KDpt130/mondays-etf-movers-fbt-xrt-cm763085,In trading on Monday the First Trust NYSE Arca Biotechnology Index Fund ETF FBT is outperforming other ETFs up about 1 6 on the day Components of that ETF showing particular strength include shares of Nektar Therapeutics NKTR up about 32 3 and shares of Agios Pharmaceuticals
AGIO,AGIO:UW,BBG004P6MJ59,Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?,2017-03-20 11:05:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/37fK0JYAkno/why-is-agios-agio-up-85-since-the-last-earnings-report-cm762694,A month has gone by since the last earnings report for Agios Pharmaceuticals Inc AGIO Shares have added about 8 5 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before
AGIO,AGIO:UW,BBG004P6MJ59,Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?,2017-03-20 08:32:08 +0000,http://finance.yahoo.com/news/why-agios-agio-8-5-083208565.html?.tsrc=rss,Agios (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AGIO,AGIO:UW,BBG004P6MJ59,Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?,2017-03-20 08:32:08 +0000,http://finance.yahoo.com/news/why-agios-agio-8-5-083208565.html,Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report?
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2017-03-13 11:49:31 +0000,http://biz.yahoo.com/e/170313/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
AGIO,AGIO:UW,BBG004P6MJ59,"7:31 am Agios Pharma announces that Celgene (<a href=""/q?s=celg"" name=""celg"">CELG</a>) has designated the development candidate focused on MTAP deleted cancers as a development candidate; Celgene will pay Agios an $8 million designation fee",2017-03-13 11:31:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#agio,"7:31 am Agios Pharma announces that Celgene (<a href=""/q?s=celg"" name=""celg"">CELG</a>) has designated the development candidate focused on MTAP deleted cancers as a development candidate; Celgene will pay Agios an $8 million designation fee"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene,2017-03-13 11:30:00 +0000,http://finance.yahoo.com/news/agios-announces-mtap-pathway-research-113000667.html,"[GlobeNewswire] - CAMBRIDGE, Mass., March 13, 2017-- Agios Pharmaceuticals, Inc. today announced that Celgene Corporation has designated the development candidate focused on MTAP deleted cancers as a development candidate ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene,2017-03-13 11:30:00 +0000,http://finance.yahoo.com/news/agios-announces-mtap-pathway-research-113000667.html?.tsrc=rss,"CAMBRIDGE, Mass., March 13, 2017-- Agios Pharmaceuticals, Inc. today announced that Celgene Corporation has designated the development candidate focused on MTAP deleted cancers as a development candidate ..."
AGIO,AGIO:UW,BBG004P6MJ59,Biotechs Among 5 Stocks Setting Up for Major Breakouts,2017-03-12 18:40:00 +0000,http://finance.yahoo.com/r/e42fc489-c9e3-316f-8c5a-16e6d820c459/biotechs-among-5-stocks-setting-up-for-major-breakouts.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's how to rake in the profits off some potential big breakouts.
AGIO,AGIO:UW,BBG004P6MJ59,Biotechs Among 5 Stocks Setting Up for Major Breakouts,2017-03-12 18:40:00 +0000,https://www.thestreet.com/story/14036771/1/biotechs-among-5-stocks-setting-up-for-major-breakouts.html?puc=yahoo&cm_ven=YAHOO,Biotechs Among 5 Stocks Setting Up for Major Breakouts
AGIO,AGIO:UW,BBG004P6MJ59,These stocks are getting whacked after the GOP unveils its Obamacare replacement,2017-03-07 16:17:12 +0000,http://finance.yahoo.com/news/these-stocks-are-getting-whacked-after-the-gop-unveils-its-obamacare-replacement-161712523.html?.tsrc=rss,"Republicans have unveiled their Obamacare replacement, and healthcare, hospital, and drug stocks aren’t super excited about it.  In early trade on Tuesday following the introduction of the bill and a Tuesday-morning tweet from President Trump which took aim at drug pricing, a number of stocks and sectors are taking a hit.  The biggest losers were drug companies, including Endo (ENDP), Valeant (VRX), and Mallinckrodt (MNK), which were all down more than 4%. Generics giants Allergan (AGN) and Mylan (MYL) were also down as much as 2% on Tuesday."
AGIO,AGIO:UW,BBG004P6MJ59,These stocks are getting whacked after the GOP unveils its Obamacare replacement,2017-03-07 16:17:12 +0000,http://finance.yahoo.com/news/these-stocks-are-getting-whacked-after-the-gop-unveils-its-obamacare-replacement-161712523.html,These stocks are getting whacked after the GOP unveils its Obamacare replacement
AGIO,AGIO:UW,BBG004P6MJ59,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM",2017-03-02 05:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AeyT2lhQlYg/fda-approves-odactra-juno-abandons-rocket-vrml-abuzz-no-tremors-for-ndrm-20170302-00244,"FDA Approves Odactra, JUNO Abandons Rocket, VRML Abuzz, No Tremors For NDRM"
AGIO,AGIO:UW,BBG004P6MJ59,​Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval,2017-03-01 20:15:15 +0000,http://www.bizjournals.com/boston/news/2017/03/01/agios-ceo-touts-path-from-a-blank-piece-of-paper.html?ana=yahoo,​Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval
AGIO,AGIO:UW,BBG004P6MJ59,​Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval,2017-03-01 20:15:15 +0000,http://finance.yahoo.com/r/048415f1-e428-3cc1-8f6e-f6357a4f2b26/agios-ceo-touts-path-from-a-blank-piece-of-paper.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"It can take a biotech decades of research and multiple late-stage trials to win approval for a novel drug.  The nine-year-old Cambridge biotech (AGIO) announced Wednesday that its leading cancer pill, enasidenib, had been accepted for review by the FDA and could win approval by this August — sooner than typical due to it being granted so-called priority review.  The application, submitted by New Jersey-based partner Celgene Corp. (CELG), is based on data from a Phase 1/2 study."
AGIO,AGIO:UW,BBG004P6MJ59,FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation,2017-03-01 12:30:00 +0000,http://finance.yahoo.com/news/fda-accepts-drug-application-grants-123000983.html?.tsrc=rss,Celgene Corporation and Agios Pharmaceuticals today announced that the U.S. Food and Drug Administration has accepted Celgene’s New Drug Application for enasidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation.
AGIO,AGIO:UW,BBG004P6MJ59,FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation,2017-03-01 12:30:00 +0000,http://finance.yahoo.com/news/fda-accepts-drug-application-grants-123000983.html,[Business Wire] - Celgene Corporation and Agios Pharmaceuticals today announced that the U.S. Food and Drug Administration has accepted Celgene’s New Drug Application for enasidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation.
AGIO,AGIO:UW,BBG004P6MJ59,Celgene: FDA Grants Priority Review For Enasidenib - Quick Facts,2017-03-01 07:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/86RcQRoowfo/celgene-fda-grants-priority-review-for-enasidenib--quick-facts-20170301-00540,Celgene: FDA Grants Priority Review For Enasidenib - Quick Facts
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017",2017-02-28 12:30:00 +0000,http://finance.yahoo.com/news/agios-present-cowen-company-37th-123000686.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 28, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017",2017-02-28 12:30:00 +0000,http://finance.yahoo.com/news/agios-present-cowen-company-37th-123000686.html?.tsrc=rss,"CAMBRIDGE, Mass., Feb. 28, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,AGIOS PHARMACEUTICALS INC Financials,2017-02-22 18:04:21 +0000,http://finance.yahoo.com/q/is?s=agio,AGIOS PHARMACEUTICALS INC Financials
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017",2017-02-21 15:59:58 +0000,http://finance.yahoo.com/r/3a59b538-2aa0-3d03-b27a-526bc7380cb1/agios-pharmaceuticals-inc-agio-us-earnings-analysis-q4-2016-by-the-numbers-february-21-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Agios Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Agios Pharmaceuticals, Inc. – Pfizer Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Celgene Corporation and GlaxoSmithKline plc Sponsored ADR (PFE-US, LLY-US, ALXN-US, CELG-US and GSK-US) that have ... Read more    
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017",2017-02-21 15:59:58 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-agio-us-earnings-analysis-q4-2016-by-the-numbers-february-21-2017/,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals 4Q Loss $1.48 Per Share,2017-02-17 17:30:00 +0000,http://www.investopedia.com/news/agios-pharmaceuticals-4q-loss-beats-street-agio/?partner=YahooSA,Agios Pharmaceuticals 4Q Loss $1.48 Per Share
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals 4Q Loss $1.48 Per Share,2017-02-17 17:30:00 +0000,http://finance.yahoo.com/r/20195100-ac83-3beb-9773-6aace1c2838b/agios-pharmaceuticals-4q-loss-beats-street-agio?partner=YahooSA&yptr=yahoo&.tsrc=rss,Agios 4Q loss beat Wall Street loss expectations.
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017",2017-02-17 17:20:03 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-agio-us-earnings-analysis-2016-by-the-numbers-february-17-2017/,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017",2017-02-17 17:20:03 +0000,http://finance.yahoo.com/r/a52abf45-9e98-358b-9471-85a0d9bd7967/agios-pharmaceuticals-inc-agio-us-earnings-analysis-2016-by-the-numbers-february-17-2017?yptr=yahoo&.tsrc=rss,"Categories:   Yahoo Finance Get free summary analysis Agios Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Agios Pharmaceuticals, Inc. – Pfizer Inc., Eli Lilly and Company, Celgene Corporation and GlaxoSmithKline plc Sponsored ADR (PFE-US, LLY-US, CELG-US and GSK-US) that have also reported for this ... Read more    
<b>(Read more...)</b>"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up,2017-02-17 16:55:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DeoHfP8NzkI/agios-pharma-agio-q4-loss-narrower-than-expected-stock-up-cm749689,Agios Pharmaceuticals Inc AGIO posted fourth quarter 2016 loss of 1 34 per share narrower than the Zacks Consensus Estimate of a loss of 1 55 but wider than the year ago loss of 1 08 Shares gained more than 8 on Feb 16 2017 following the earnings results In fact Agios s
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up,2017-02-17 14:27:02 +0000,http://finance.yahoo.com/news/agios-pharma-agio-q4-loss-142702400.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up,2017-02-17 14:27:02 +0000,http://finance.yahoo.com/news/agios-pharma-agio-q4-loss-142702400.html,Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
AGIO,AGIO:UW,BBG004P6MJ59,Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT,2017-02-16 16:34:01 +0000,http://finance.yahoo.com/news/edited-transcript-agio-earnings-conference-163401011.html?.tsrc=rss,Q4 2016 Agios Pharmaceuticals Inc Earnings Call
AGIO,AGIO:UW,BBG004P6MJ59,Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT,2017-02-16 16:34:01 +0000,http://finance.yahoo.com/news/edited-transcript-agio-earnings-conference-163401011.html,Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y,2017-02-16 14:56:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0JOyolDu8HQ/agios-agio-q4-loss-narrower-than-expected-revenues-up-yy-cm748875,Agios Pharmaceuticals Inc AGIO is a development stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders The company has several interesting candidates in its pipeline Its cancer pipeline comprises enasidenib IDH2
AGIO,AGIO:UW,BBG004P6MJ59,Implied IYH Analyst Target Price: $169,2017-02-16 14:55:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e_43sYmTnTw/implied-iyh-analyst-target-price-169-cm748767,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y,2017-02-16 13:53:01 +0000,http://finance.yahoo.com/news/agios-agio-q4-loss-narrower-135301369.html?.tsrc=rss,"Agios posted narrower-than-expected loss in the fourth quarter of 2016. Our consensus called for a loss of $1.55 per share, and the company reported a loss of $1.34."
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y,2017-02-16 13:53:01 +0000,http://finance.yahoo.com/news/agios-agio-q4-loss-narrower-135301369.html,Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today,2017-02-16 13:00:00 +0000,http://biz.yahoo.com/cc/0/155600.html,Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2017-02-16 12:21:59 +0000,http://biz.yahoo.com/e/170216/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 4Q loss,2017-02-16 12:16:44 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-reports-4q-loss-121644002.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had a loss of $1.34 per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 4Q loss,2017-02-16 12:16:44 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-reports-4q-loss-121644929.html,Agios Pharmaceuticals reports 4Q loss
AGIO,AGIO:UW,BBG004P6MJ59,Q4 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open,2017-02-16 12:07:03 +0000,http://biz.yahoo.com/research/earncal/20170216.html?t=agio,Q4 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones,2017-02-16 12:01:00 +0000,http://finance.yahoo.com/news/agios-reports-fourth-quarter-full-120100839.html?.tsrc=rss,-Ivosidenib NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of 2017-. -AG-348 Pivotal Trial Design Update Expected in the Third Quarter ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones,2017-02-16 12:01:00 +0000,http://finance.yahoo.com/news/agios-reports-fourth-quarter-full-120100839.html,[GlobeNewswire] - -Ivosidenib NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of 2017-. -AG-348 Pivotal Trial Design Update Expected in the Third Quarter ...
AGIO,AGIO:UW,BBG004P6MJ59,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More",2017-02-15 13:47:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-134701280.html,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More"
AGIO,AGIO:UW,BBG004P6MJ59,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More",2017-02-15 13:47:01 +0000,http://finance.yahoo.com/news/drug-stocks-q4-earnings-slated-134701280.html?.tsrc=rss,The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?,2017-02-10 16:21:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d0Mb7ThaZ-A/agios-pharmaceuticals-agio-q4-earnings-whats-in-store-cm746246,Agios Pharmaceuticals Inc AGIO is scheduled to report fourth quarter and full year 2016 results on Feb 16 Agios shares gained 10 3 so far this year while the Zacks classified Medical Products industry witnessed an increase of 5 3 Agios performance has been far
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?,2017-02-10 14:29:02 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-agio-q4-earnings-142902997.html?.tsrc=rss,"Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?,2017-02-10 14:29:02 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-agio-q4-earnings-142902997.html,Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017",2017-02-09 12:30:00 +0000,http://finance.yahoo.com/news/agios-webcast-conference-call-fourth-123000706.html?.tsrc=rss,"CAMBRIDGE, Mass., Feb. 09, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017",2017-02-09 12:30:00 +0000,http://finance.yahoo.com/news/agios-webcast-conference-call-fourth-123000706.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Feb. 09, 2017-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Analysts' Actions -- Chipotle, Disney, Brinker, J.P. Morgan and More",2017-01-17 13:09:00 +0000,http://finance.yahoo.com/news/analysts-actions-chipotle-disney-brinker-130900025.html,"Analysts' Actions -- Chipotle, Disney, Brinker, J.P. Morgan and More"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma upgraded by Oppenheimer,2017-01-17 11:16:09 +0000,http://finance.yahoo.com/q/ud?s=AGIO,Agios Pharma upgraded by Oppenheimer
AGIO,AGIO:UW,BBG004P6MJ59,Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO),2017-01-13 15:39:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tb7S3m1YN9M/falling-earnings-estimates-signal-weakness-ahead-for-agios-pharmaceuticals-agio-cm733203,Similar to wise buying decisions exiting certain underperformers at the right time helps maximize portfolio returns Selling off losers can be difficult but if both the share price and estimates are falling it could be time to get rid of the security before more losses hit your
AGIO,AGIO:UW,BBG004P6MJ59,Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO),2017-01-13 13:51:01 +0000,http://finance.yahoo.com/news/falling-earnings-estimates-signal-weakness-135101199.html?.tsrc=rss,Agios Pharmaceuticals (AGIO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
AGIO,AGIO:UW,BBG004P6MJ59,Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO),2017-01-13 13:51:01 +0000,http://finance.yahoo.com/news/falling-earnings-estimates-signal-weakness-135101199.html,Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Sank 34.4% in 2016,2017-01-10 20:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ljj26ugoWfI/why-agios-pharmaceuticals-sank-344-in-2016-cm731846,Image source Getty Images What happened Investors in Agios Pharmaceuticals NASDAQ AGIO a company focused on metabolic disorders had a wild ride in 2016 The company s stock traded erratically all year long based on the headlines of the day but it ultimately lost more
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Sank 34.4% in 2016,2017-01-10 19:23:07 +0000,http://www.fool.com/investing/2017/01/10/why-agios-pharmaceuticals-sank-344-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Agios Pharmaceuticals Sank 34.4% in 2016
AGIO,AGIO:UW,BBG004P6MJ59,"Commit To Purchase Agios Pharmaceuticals At $35, Earn 17.8% Annualized Using Options",2017-01-10 17:53:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oQ6xrCSwHYY/commit-to-purchase-agios-pharmaceuticals-at-35-earn-178-annualized-using-options-cm731769,Investors eyeing a purchase of Agios Pharmaceuticals Inc Symbol AGIO shares but cautious about paying the going market price of 41 46 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
AGIO,AGIO:UW,BBG004P6MJ59,"Gainers & Losers Of The Day: DFFN, ETRM, GNVC, EGRX, ADHD...",2017-01-09 21:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YeC3pqGuWNw/gainers--losers-of-the-day-dffn-etrm-gnvc-egrx-adhd-20170109-01108,"Gainers & Losers Of The Day: DFFN, ETRM, GNVC, EGRX, ADHD..."
AGIO,AGIO:UW,BBG004P6MJ59,Implied IYH Analyst Target Price: $169,2017-01-09 15:50:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LseEZMqsXr0/implied-iyh-analyst-target-price-169-cm730978,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure",2017-01-09 13:03:45 +0000,http://biz.yahoo.com/e/170109/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017,2017-01-09 12:30:00 +0000,http://finance.yahoo.com/news/agios-announces-key-upcoming-milestones-123000605.html,[GlobeNewswire] - -Enasidenib NDA Submitted for IDH2m Relapsed/Refractory Acute Myeloid Leukemia-. -AG-120 NDA Submission for IDH1m R/R AML Planned by Year End 2017-. -AG-348 Advancing to Pivotal Development in PK Deficiency-....
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh",2017-01-04 21:47:38 +0000,http://biz.yahoo.com/e/170104/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh"
AGIO,AGIO:UW,BBG004P6MJ59,"Shire, Agios add former Genentech CEO as board member",2017-01-03 20:00:08 +0000,http://www.bizjournals.com/boston/news/2017/01/03/shire-agios-add-former-genentech-ceo-as-board.html?ana=yahoo,"Shire, Agios add former Genentech CEO as board member"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Appoints Ian Clark to Board of Directors,2017-01-03 13:13:08 +0000,http://www.publicnow.com/view/05435D6CBDD185CC2FCE496A65CC29D884C68C81,"[at noodls] - CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the appointment ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Appoints Ian Clark to Board of Directors,2017-01-03 13:00:00 +0000,http://finance.yahoo.com/news/agios-appoints-ian-clark-board-130000301.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Jan. 03, 2017-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the appointment of Ian Clark to its board ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017",2017-01-03 12:30:00 +0000,http://finance.yahoo.com/news/agios-present-35th-annual-j-123000966.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Jan. 03, 2017-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : December 20, 2016",2016-12-20 14:41:09 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-value-analysis-nasdaqagio-december-20-2016/,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : December 20, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Stops Development of PKR Activator AG-519, Stock Falls",2016-12-19 16:00:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D-gzJNMFbrw/agios-stops-development-of-pkr-activator-ag-519-stock-falls-cm723207,Agios Pharmaceuticals Inc s AGIO shares tumbled 19 4 after the company announced that it is has decided to discontinue the development of one of its pyruvate kinase R PKR activator AG 519 The decision was taken after the verbal notification of a clinical hold by the FDA which led
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Stops Development of PKR Activator AG-519, Stock Falls",2016-12-19 13:47:01 +0000,http://finance.yahoo.com/news/agios-stops-development-pkr-activator-134701967.html,"Agios Stops Development of PKR Activator AG-519, Stock Falls"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : December 19, 2016",2016-12-19 12:49:21 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-agio-us-december-19-2016/,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : December 19, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Inc. Got Hammered Today,2016-12-16 20:57:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dFQNDviWNPs/why-agios-pharmaceuticals-inc-got-hammered-today-cm722723,Image source Getty Images What happened Agios Pharmaceuticals NASDAQ AGIO is down almost 20 at 1 19 p m EST after the biotech issued an update on its 160 pyruvate kinase R PKR program yesterday after the bell So what When a company says it s providing an update
AGIO,AGIO:UW,BBG004P6MJ59,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Agios Pharmaceuticals, Inc. - AGIO",2016-12-16 19:41:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-194100531.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 16, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (""Agios"" or the ""Company"") (NASDAQ: AGIO). ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Health Care Sector Update for 12/16/2016: AGIO,EVOK,RXII",2016-12-16 19:16:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gdwo9L4oNAw/health-care-sector-update-for-12162016-agioevokrxii-cm722682,Top Health Care StocksTop Health Care Stocks JNJ 0 06 JNJ 0 06 PFE 0 53 PFE 0 53 MRK 1 67 MRK 1 67 ABT 0 18 ABT 0 18 AMGN 0 76 AMGN 0 76 Health care stocks were little changed in afternoon trade with the NYSE Health Care Index climbing less than 0 1 while shares of health
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Inc. Got Hammered Today,2016-12-16 19:01:23 +0000,http://www.fool.com/investing/2016/12/16/why-agios-pharmaceuticals-inc-got-hammered-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Agios Pharmaceuticals Inc. Got Hammered Today
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma Shares Crushed Under Weight Of Clinical Setback,2016-12-16 17:44:05 +0000,http://finance.yahoo.com/news/agios-pharma-shares-crushed-under-174405338.html,Agios Pharma Shares Crushed Under Weight Of Clinical Setback
AGIO,AGIO:UW,BBG004P6MJ59,"INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors -- AGIO",2016-12-16 16:08:00 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-160800860.html,"[PR Newswire] - NEW YORK, Dec. 16, 2016 /PRNewswire/ -- Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc. (""Agios"" or the ""Company"") (NASDAQ: AGIO) ..."
AGIO,AGIO:UW,BBG004P6MJ59,Gilead Must Pay Merck $2.5 Billion For Hep C Patent; Agios Stock Anemic,2016-12-16 13:29:29 +0000,http://www.investors.com/news/technology/gilead-must-pay-merck-2-5-billion-in-hep-c-patent-fight-agios-stock-anemic/,Gilead Must Pay Merck $2.5 Billion For Hep C Patent; Agios Stock Anemic
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc. (AGIO) Is Down Sharply After AG-519 Discontinued,2016-12-16 09:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nllLUCeF4R0/agios-pharmaceuticals-inc-agio-is-down-sharply-after-ag519-discontinued-20161216-00362,Agios Pharmaceuticals Inc. (AGIO) Is Down Sharply After AG-519 Discontinued
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc to Provide Update on PKR Program Call scheduled for 5:00 pm ET today,2016-12-15 22:00:00 +0000,http://biz.yahoo.com/cc/7/155067.html,Agios Pharmaceuticals Inc to Provide Update on PKR Program Call scheduled for 5:00 pm ET today
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharma shares dive after anemia treatment development halted,2016-12-15 21:44:09 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=95842AD0-7ED4-43C6-BD53-D4E65111EC44&siteid=yhoof2,Agios Pharma shares dive after anemia treatment development halted
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-12-15 21:38:11 +0000,http://biz.yahoo.com/e/161215/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
AGIO,AGIO:UW,BBG004P6MJ59,Agios drops drug for blood disorder due to side effects,2016-12-15 21:33:00 +0000,http://finance.yahoo.com/video/agios-drops-drug-blood-disorder-213300529.html,Agios drops drug for blood disorder due to side effects
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup",2016-12-15 21:01:00 +0000,https://www.thestreet.com/story/13927978/1/agios-shelves-drug-for-rare-anemia-disorder-due-to-liver-toxicity-switches-to-backup-compound.html?puc=yahoo&cm_ven=YAHOO,"Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Provides Update on PKR Program,2016-12-15 21:01:00 +0000,http://finance.yahoo.com/news/agios-provides-pkr-program-210100851.html,[GlobeNewswire] - -Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback-. -Lead PKR Activator AG-348 Advancing into Pivotal Development in Pyruvate Kinase Deficiency-. -Company to Host Conference ...
AGIO,AGIO:UW,BBG004P6MJ59,Flagship Ventures Evolves Name To Flagship Pioneering,2016-12-15 05:01:00 +0000,http://finance.yahoo.com/news/flagship-ventures-evolves-name-flagship-050100949.html,"[PR Newswire] - CAMBRIDGE, Mass., Dec. 15, 2016 /PRNewswire/ -- As Flagship Ventures enters its 17th year, the firm announced today that it is changing its name to Flagship Pioneering. The announcement comes as the firm closed an innovative, follow-on capital pool, capping a year of unprecedented achievements. The $285 million Special Opportunities Fund operates alongside Flagship's most recent early-stage family of funds, Fund V, which totalled $585 million and closed in 2015. This brings the total in active capital being deployed within the next generation of ventures to $870 million, and the overall funds managed by Flagship Pioneering to $1.75 billion. ""The inspiration behind the evolved name comes from our unique process of 'Pioneering' through which we envision and make unforeseen innovations that have disruptive value potential, and systematically create new ventures to realize their promise,"" said Noubar Afeyan, founder and CEO of Flagship Pioneering."
AGIO,AGIO:UW,BBG004P6MJ59,3 Drugs Heading to the FDA Soon,2016-12-12 14:59:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4ggZtEWLFqc/3-drugs-heading-to-the-fda-soon-cm719977,It s incredibly difficult to usher a drug successfully through scientifically controlled clinical trials to the FDA but when drug developers pull it off the payoff for investors can be huge At least that s what investors in Flexion Therapeutics NASDAQ FLXN Kite
AGIO,AGIO:UW,BBG004P6MJ59,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Agios Pharmaceuticals, Inc.",2016-12-09 01:50:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-015000225.html,"[Business Wire] - Khang & Khang LLP announces that it is investigating claims against Agios Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
AGIO,AGIO:UW,BBG004P6MJ59,"Robbins Arroyo LLP Is Investigating the Officers and Directors of Agios Pharmaceuticals, Inc. (AGIO) on Behalf of Shareholders",2016-12-08 23:37:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-investigating-officers-233700557.html,"[Business Wire] - Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Agios Pharmaceuticals, Inc. violated federal securities laws by issuing materially misleading business information to the investing public."
AGIO,AGIO:UW,BBG004P6MJ59,"Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus",2016-12-07 13:49:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-actelion-remains-134901750.html,"Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus"
AGIO,AGIO:UW,BBG004P6MJ59,"EQUITY ALERT: Lundin Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",2016-12-07 02:41:00 +0000,http://finance.yahoo.com/news/equity-alert-lundin-law-pc-024100894.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Agios Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
AGIO,AGIO:UW,BBG004P6MJ59,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Agios Pharmaceuticals, Inc. and Certain Officers and Directors",2016-12-06 22:40:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-224000072.html,"[Business Wire] - Levi & Korsinsky, LLP announces that it has commenced an investigation of Agios Pharmaceuticals, Inc. concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Anemia Drug Probed For Safety Issues (AGIO),2016-12-06 19:15:00 +0000,http://www.investopedia.com/news/agios-plunges-anemia-drug-safety-concerns-agio/?partner=YahooSA,Agios Anemia Drug Probed For Safety Issues (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,"SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",2016-12-06 17:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-170000078.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Agios Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
AGIO,AGIO:UW,BBG004P6MJ59,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Agios Pharmaceuticals, Inc. (AGIO)",2016-12-06 15:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151000257.html,"[PR Newswire] - NEW YORK, Dec. 6, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Agios Pharmaceuticals, Inc. ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Falls on Safety Concerns (AGIO),2016-12-06 13:55:00 +0000,http://www.investopedia.com/news/agios-falls-safety-concerns-agio/?partner=YahooSA,Agios Falls on Safety Concerns (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-12-06 12:48:34 +0000,http://biz.yahoo.com/e/161206/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : December 6, 2016",2016-12-06 12:28:10 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-agio-us-december-6-2016/,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : December 6, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies,2016-12-06 00:30:00 +0000,http://finance.yahoo.com/news/agios-announces-clinical-data-dose-003000004.html,"[GlobeNewswire] - -Overall Response Rate of 38% and Complete Remission Rate of 18% with Patients on Study up to 24.2 Months-. -For Relapsed/Refractory Acute Myeloid Leukemia Patients, Overall Response Rate of 33% and Complete ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Why Sears Holdings, Agios Pharmaceuticals, and Tailored Brands Slumped Today",2016-12-05 23:39:00 +0000,http://www.fool.com/investing/2016/12/05/why-sears-holdings-agios-pharmaceuticals-and-tailo.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Sears Holdings, Agios Pharmaceuticals, and Tailored Brands Slumped Today"
AGIO,AGIO:UW,BBG004P6MJ59,"IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Agios Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm",2016-12-05 22:30:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-223000863.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Agios Pharmaceuticals, Inc. concerning possible violations of federal securities laws."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceutical shares tank amid safety concerns about drug,2016-12-05 21:52:25 +0000,http://www.cnbc.com/id/104147628?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104147628,Agios Pharmaceutical shares tank amid safety concerns about drug
AGIO,AGIO:UW,BBG004P6MJ59,Agios CEO: We have two medicines that will change lives,2016-12-05 20:33:00 +0000,http://finance.yahoo.com/video/agios-ceo-two-medicines-change-203300479.html,Agios CEO: We have two medicines that will change lives
AGIO,AGIO:UW,BBG004P6MJ59,"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Shareholders of Agios Pharmaceuticals, Inc. - AGIO",2016-12-05 20:19:00 +0000,http://finance.yahoo.com/news/shareholder-alert-pomerantz-law-firm-201900746.html,"[PR Newswire] - NEW YORK, Dec. 5, 2016 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (""Agios"" or the ""Company"") (AGIO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Agios and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934."
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Inc Stock Fell Sharply Today,2016-12-05 18:38:28 +0000,http://www.fool.com/investing/2016/12/05/why-agios-pharmaceuticals-inc-stock-fell-sharply-t.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Agios Pharmaceuticals Inc Stock Fell Sharply Today
AGIO,AGIO:UW,BBG004P6MJ59,Here are 4 Mass. biotechs making noise at the ASH conference so far,2016-12-05 18:00:08 +0000,http://www.bizjournals.com/boston/news/2016/12/05/here-are-4-mass-biotechs-making-noise-at-the-ash.html?ana=yahoo,Here are 4 Mass. biotechs making noise at the ASH conference so far
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc. (AGIO) Is Sinking In Early Trade,2016-12-05 09:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FQYsgWKVots/agios-pharmaceuticals-inc-agio-is-sinking-in-early-trade-20161205-00596,Agios Pharmaceuticals Inc. (AGIO) Is Sinking In Early Trade
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency,2016-12-05 00:30:00 +0000,http://finance.yahoo.com/news/agios-announces-data-ag-348-003000063.html,"[GlobeNewswire] - -AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin Increases in 15 of 26 Patients with at Least One Missense Mutation and 15 out of 32 Patients Overall-. -AG-519 ..."
AGIO,AGIO:UW,BBG004P6MJ59,Here is What Hedge Funds Think About Agios Pharmaceuticals Inc (AGIO),2016-11-30 11:15:21 +0000,http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-agios-pharmaceuticals-inc-agio-493719/,Here is What Hedge Funds Think About Agios Pharmaceuticals Inc (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,Agios Presents Encouraging Glioma Data (AGIO),2016-11-21 16:29:00 +0000,http://www.investopedia.com/news/agios-presents-encouraging-glioma-data-agio/?partner=YahooSA,Agios Presents Encouraging Glioma Data (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,Agios Presents Data from Dose Expansion Study of AG-120,2016-11-21 15:52:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pnlu8hHVlXE/agios-presents-data-from-dose-expansion-study-of-ag-120-cm711888,Agios Pharmaceuticals Inc AGIO announced first data from a phase I study on AG 120 an oral first in class IDH1 mutant inhibitor which is being evaluated as a single agent for the treatment of isocitrate dehydrogenase 1 IDH1 mutant positive glioma and chondrosarcoma The study is part
AGIO,AGIO:UW,BBG004P6MJ59,Agios Presents Data from Dose Expansion Study of AG-120,2016-11-21 14:00:02 +0000,http://finance.yahoo.com/news/agios-presents-data-dose-expansion-140002372.html,Agios Presents Data from Dose Expansion Study of AG-120
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma,2016-11-18 13:00:18 +0000,http://www.publicnow.com/view/73BBDCACAA7F4020CC7DCF1A4A1B7F195D84466A,[at noodls] - - Durable Stable Disease Observed for Patients with Non-enhancing Low Grade Glioma and Chondrosarcoma Patients; 42% of Glioma Patients Still on Treatment - - AG-120 Well-tolerated in Pre-Treated Populations ...
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits",2016-11-18 12:31:09 +0000,http://biz.yahoo.com/e/161118/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Breaks Price Target (AGIO),2016-11-16 14:52:00 +0000,http://www.investopedia.com/news/agios-breaks-price-target-agio/?partner=YahooSA,Agios Breaks Price Target (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Reaches Analyst Target Price,2016-11-15 15:28:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4-Vo-q4thbo/agios-pharmaceuticals-reaches-analyst-target-price-cm709414,In recent trading shares of Agios Pharmaceuticals Inc Symbol AGIO have crossed above the average analyst 12 month target price of 64 50 changing hands for 66 98 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
AGIO,AGIO:UW,BBG004P6MJ59,"ETFs with exposure to Agios Pharmaceuticals, Inc. : November 14, 2016",2016-11-14 17:47:47 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-agios-pharmaceuticals-inc-november-14-2016/,"ETFs with exposure to Agios Pharmaceuticals, Inc. : November 14, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016",2016-11-10 14:49:48 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-agio-us-earnings-analysis-q3-2016-by-the-numbers-november-10-2016/,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers",2016-11-09 21:44:44 +0000,http://biz.yahoo.com/e/161109/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers"
AGIO,AGIO:UW,BBG004P6MJ59,Spark Therapeutics Inc (ONCE) and Other Profitable Healthcare Picks of Casdin Capital,2016-11-05 22:33:30 +0000,http://www.insidermonkey.com/blog/spark-therapeutics-inc-once-and-other-profitable-healthcare-picks-of-casdin-capital-485077/,Spark Therapeutics Inc (ONCE) and Other Profitable Healthcare Picks of Casdin Capital
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q3 Loss Wider than Expected, Pipeline in Focus",2016-11-04 20:23:08 +0000,http://finance.yahoo.com/news/agios-agio-q3-loss-wider-192307428.html,"Agios (AGIO) Q3 Loss Wider than Expected, Pipeline in Focus"
AGIO,AGIO:UW,BBG004P6MJ59,Agios 3Q Loss $1.63/Shr Wider than Expected (AGIO),2016-11-04 15:50:00 +0000,http://www.investopedia.com/news/agios-3q-loss-and-revenue-below-street-agio/?partner=YahooSA,Agios 3Q Loss $1.63/Shr Wider than Expected (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,Edited Transcript of AGIO earnings conference call or presentation 3-Nov-16 12:00pm GMT,2016-11-03 22:45:44 +0000,http://finance.yahoo.com/news/edited-transcript-agio-earnings-conference-224544910.html,Edited Transcript of AGIO earnings conference call or presentation 3-Nov-16 12:00pm GMT
AGIO,AGIO:UW,BBG004P6MJ59,Why Celgene Corp Is a Better Buy Than Gilead Sciences,2016-11-03 21:08:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tsknLK6xbUg/why-celgene-corp-is-a-better-buy-than-gilead-sciences-cm703624,Image source Getty Images Over the past five years there have perhaps been no large cap biotech companies that have been as successful as Celgene Corp NASDAQ CELG and Gilead Sciences NASDAQ GILD New drug launches have resulted in sales and profit surging higher at
AGIO,AGIO:UW,BBG004P6MJ59,This Healthcare Fund Just Had A Huge Q3: Here’s How,2016-11-03 20:59:00 +0000,http://www.insidermonkey.com/blog/this-healthcare-fund-just-had-a-huge-q3-heres-how-484834/,This Healthcare Fund Just Had A Huge Q3: Here’s How
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Posts Wider-than-Expected Loss in Q3,2016-11-03 15:10:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FYkq1z0uD2o/agios-agio-posts-wider-than-expected-loss-in-q3-cm703216,Agios Pharmaceuticals I nc AGIO is a development stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders The company has several interesting candidates in its pipeline Its cancer pipeline comprises enasidenib IDH2
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 3Q loss,2016-11-03 14:10:50 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-reports-3q-loss-141050593.html,Agios Pharmaceuticals reports 3Q loss
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Posts Wider-than-Expected Loss in Q3,2016-11-03 13:15:01 +0000,http://finance.yahoo.com/news/agios-agio-posts-wider-expected-131501397.html,Agios (AGIO) Posts Wider-than-Expected Loss in Q3
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting,2016-11-03 13:14:17 +0000,http://finance.yahoo.com/news/agios-present-data-pkr-idh-131417084.html,"[GlobeNewswire] - -Updated Safety and Efficacy Data from AG-348, AG-519 and Completed Dose Escalation Portion of AG-120 Study to be Highlighted in Oral and Poster Presentations-. -Company to Host Investor Event and Webcast ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 3, 2016",2016-11-03 12:32:17 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-agio-us-november-3-2016/,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : November 3, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today,2016-11-03 12:00:00 +0000,http://biz.yahoo.com/cc/3/154563.html,Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs,2016-11-03 11:18:21 +0000,http://www.publicnow.com/view/7D856E46507380FB0151E975A3989B0F4FBA2204,[at noodls] - - Enasidenib (AG-221) on Track for NDA Submission in IDH2m Positive Relapsed/Refractory AML by Year End - - Follow-on Offering Raised Approximately $173 Million in September; Updated 2016 Year End Cash ...
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-11-03 11:15:20 +0000,http://biz.yahoo.com/e/161103/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
AGIO,AGIO:UW,BBG004P6MJ59,Q3 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open,2016-11-03 11:07:04 +0000,http://biz.yahoo.com/research/earncal/20161103.html?t=agio,Q3 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open
AGIO,AGIO:UW,BBG004P6MJ59,"Medical Product Nov 3 Earnings Preview: HRC, AGIO, PEN, PODD",2016-11-02 14:12:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5WAydZJRnQc/medical-product-nov-3-earnings-preview-hrc-agio-pen-podd-cm702280,With Q3 earnings reports already out from more than 66 4 of the S amp P 500 members 332 companies our latest Earnings Outlook has exhibited an improving trend so far Proceeding deep into the second half of the earnings reporting cycle we are further assured about this quarter turning out
AGIO,AGIO:UW,BBG004P6MJ59,"Medical Product Nov 3 Earnings Preview: HRC, AGIO, PEN, PODD",2016-11-02 12:28:12 +0000,http://finance.yahoo.com/news/medical-product-nov-3-earnings-122812595.html,"Medical Product Nov 3 Earnings Preview: HRC, AGIO, PEN, PODD"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016",2016-11-01 11:01:00 +0000,http://finance.yahoo.com/news/agios-present-25th-annual-credit-110100169.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Nov. 01, 2016-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO): Will the Stock Disappoint in Q3 Earnings?,2016-10-31 22:14:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-NwyXzVMUvI/agios-agio-will-the-stock-disappoint-in-q3-earnings-cm701398,Agios Pharmaceuticals Inc AGIO is scheduled to report third quarter 2016 results on Nov 3 before the opening bell Agios performance has been far from encouraging with company missing estimates thrice in the trailing four quarters Overall Agios has recorded an average negative
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO): Will the Stock Disappoint in Q3 Earnings?,2016-10-31 20:34:08 +0000,http://finance.yahoo.com/news/agios-agio-stock-disappoint-q3-203408402.html,Agios (AGIO): Will the Stock Disappoint in Q3 Earnings?
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016",2016-10-27 11:16:20 +0000,http://www.publicnow.com/view/B61ED0AF614320A4F261F0FA81996250EC809479,"[at noodls] - CAMBRIDGE, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the ..."
AGIO,AGIO:UW,BBG004P6MJ59,Celgene/Agios Ink Deals with Abbott to Identify IDH Mutations,2016-10-13 16:45:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q06uK9NTKF4/celgeneagios-ink-deals-with-abbott-to-identify-idh-mutations-cm692955,Celgene Corporation CELG and Agios Pharmaceuticals Inc AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase IDH mutations in patients with acute myeloid
AGIO,AGIO:UW,BBG004P6MJ59,Abbott Develops AML Tests With Celgene and Agios,2016-10-13 16:05:02 +0000,http://finance.yahoo.com/news/abbott-develops-aml-tests-celgene-160502670.html,Abbott Develops AML Tests With Celgene and Agios
AGIO,AGIO:UW,BBG004P6MJ59,Celgene/Agios Ink Deals with Abbott to Identify IDH Mutations,2016-10-13 14:10:02 +0000,http://finance.yahoo.com/news/celgene-agios-ink-deals-abbott-141002276.html,Celgene/Agios Ink Deals with Abbott to Identify IDH Mutations
AGIO,AGIO:UW,BBG004P6MJ59,Blog Coverage Celgene and Agios Team up with Abbott,2016-10-13 13:01:55 +0000,http://news.investornetwork.com/2016/10/13/blog-coverage-celgene-and-agios-team-up-with-abbott/?1=1&1476363715,Blog Coverage Celgene and Agios Team up with Abbott
AGIO,AGIO:UW,BBG004P6MJ59,"Celgene, Agios, Abbott Team For Test (CELG, AGIO)",2016-10-12 16:40:00 +0000,http://www.investopedia.com/news/celgene-and-agios-partner-abbott-celg-agio/?partner=YahooSA,"Celgene, Agios, Abbott Team For Test (CELG, AGIO)"
AGIO,AGIO:UW,BBG004P6MJ59,Stocks Close Roughly Flat Following Fed Minutes - U.S. Commentary,2016-10-12 16:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fA7WKM-Z2Kg/stocks-close-roughly-flat-following-fed-minutes--us-commentary-20161012-00776,Stocks Close Roughly Flat Following Fed Minutes - U.S. Commentary
AGIO,AGIO:UW,BBG004P6MJ59,"Here’s Why Stanley Black & Decker, Celgene Corporation, and Three Other Stocks Are Trending Today",2016-10-12 14:41:57 +0000,http://www.insidermonkey.com/blog/heres-why-stanley-black-decker-celgene-corporation-and-three-other-stocks-are-trending-today-480807/,"Here’s Why Stanley Black & Decker, Celgene Corporation, and Three Other Stocks Are Trending Today"
AGIO,AGIO:UW,BBG004P6MJ59,Celgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML,2016-10-12 11:53:10 +0000,http://www.publicnow.com/view/99A11E8E335F0EB7571182EDDAA5F7A140B3FBFB,[at noodls] - Companion diagnostic technology to be utilized with enasidenib (AG-221/CC-90007) and AG-120 development programs for relapsed/refractory acute myeloid leukemia (AML) Approximately 20% of AML patients have ...
AGIO,AGIO:UW,BBG004P6MJ59,Celgene & Agios To Collaborate With Abbott To Identify IDH Mutations In AML,2016-10-12 07:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WBulaAOoqoc/celgene--agios-to-collaborate-with-abbott-to-identify-idh-mutations-in-aml-20161012-00231,Celgene & Agios To Collaborate With Abbott To Identify IDH Mutations In AML
AGIO,AGIO:UW,BBG004P6MJ59,Is Celgene the Smartest Buyer in Biotech?,2016-10-02 00:13:39 +0000,http://www.fool.com/investing/2016/09/30/is-celgene-the-smartest-buyer-in-biotech.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Celgene the Smartest Buyer in Biotech?
AGIO,AGIO:UW,BBG004P6MJ59,Is Celgene the Smartest Buyer in Biotech?,2016-10-01 01:21:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8zdnk8Aiqdw/is-celgene-the-smartest-buyer-in-biotech-cm687412,Image source Getty Images Celgene NASDAQ CELG is well known for its superstar drugs including 160 blood cancer drug Revlimid which hit 5 8 billion in sales last year and could well reach 10 billion in 2020 160 But what fewer investors realize is how the company
AGIO,AGIO:UW,BBG004P6MJ59,Analysts Forecast 14% Upside For IYH,2016-09-27 15:23:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sG_pQgaEPlA/analysts-forecast-14-upside-for-iyh-cm685262,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares,2016-09-20 20:18:05 +0000,http://www.publicnow.com/view/7AED7A1C10FE5186CA1A70117580DCFD9AFA6E1F,"[at noodls] - CAMBRIDGE, Mass., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Stocks Close Slightly Higher Ahead Of BoJ, Fed Decisions - U.S. Commentary",2016-09-20 16:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cK2hLD_wDLs/stocks-close-slightly-higher-ahead-of-boj-fed-decisions--us-commentary-20160920-01178,"Stocks Close Slightly Higher Ahead Of BoJ, Fed Decisions - U.S. Commentary"
AGIO,AGIO:UW,BBG004P6MJ59,Floor seen for Agios Pharmaceuticals,2016-09-16 11:16:30 +0000,http://finance.yahoo.com/news/floor-seen-agios-pharmaceuticals-111630100.html,Floor seen for Agios Pharmaceuticals
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta",2016-09-15 20:48:16 +0000,http://biz.yahoo.com/e/160915/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta"
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Raise $150 million in Stock Offering,2016-09-15 16:37:00 +0000,http://www.investopedia.com/news/agios-raise-150-million-stock-offering/?partner=YahooSA,Agios to Raise $150 million in Stock Offering
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Pricing of $150 Million Public Offering of Common Stock,2016-09-15 00:58:08 +0000,http://www.publicnow.com/view/2F17C848991438BF2B8AEEC8C3296DE107F72786,"[at noodls] - CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common stock at ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Why 5 Stocks, Including Macy’s and Coach, Are Going Viral Today",2016-09-14 16:22:01 +0000,http://www.insidermonkey.com/blog/why-5-stocks-including-macys-and-coach-are-going-viral-today-474608/,"Why 5 Stocks, Including Macy’s and Coach, Are Going Viral Today"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Proposed Offering of Common Stock,2016-09-13 20:38:07 +0000,http://www.publicnow.com/view/44D0B80BDF72B1C365084808A7EAF040C6056A3D,"[at noodls] - CAMBRIDGE, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $150 million of ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : September 9, 2016",2016-09-09 17:51:28 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-value-analysis-nasdaqagio-september-9-2016/,"Agios Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AGIO) : September 9, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,Why Do You Guys Run an Education Company?,2016-09-08 20:20:11 +0000,http://finance.yahoo.com/tumblr/blog-why-do-you-guys-run-an-education-company-202017320.html,Why Do You Guys Run an Education Company?
AGIO,AGIO:UW,BBG004P6MJ59,"Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up",2016-09-08 15:21:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oIyyaYJvjew/agios-agio-partner-celgene-to-file-for-enasidenib-stock-up-cm676183,Agios Pharmaceuticals Inc s AGIO shares were up almost 26 after the company revealed in an 8 K filing that its collaboration partner Celgene Corporation CELG will submit a new drug application NDA for enasidenib AG 221 for the treatment of patients with relapsed and or refractory
AGIO,AGIO:UW,BBG004P6MJ59,Blog Coverage Celgene Partner of Agios Pharma Plans NDA to Get FDA Approval for Blood Cancer Drug AG 221,2016-09-08 13:16:40 +0000,http://news.investornetwork.com/2016/09/08/blog-coverage-celgene-partner-of-agios-pharma-plans-nda-to-get-fda-approval-for-blood-cancer-drug-ag-221/?1=1&1473340600,Blog Coverage Celgene Partner of Agios Pharma Plans NDA to Get FDA Approval for Blood Cancer Drug AG 221
AGIO,AGIO:UW,BBG004P6MJ59,"Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up",2016-09-08 13:09:01 +0000,http://finance.yahoo.com/news/agios-agio-partner-celgene-file-130901714.html,"Agios' (AGIO) Partner Celgene to File for Enasidenib, Stock Up"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : September 8, 2016",2016-09-08 12:03:26 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bullish-manner-agio-us-september-8-2016/,"Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : September 8, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Stock Soars As Partner Celgene Preps Drug Filing,2016-09-07 20:40:24 +0000,http://www.investors.com/news/technology/agios-stock-soars-as-partner-celgene-preps-drug-filing/,Agios Stock Soars As Partner Celgene Preps Drug Filing
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Inc Stock Skyrocketed Today,2016-09-07 19:18:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zAwWC4raKnQ/why-agios-pharmaceuticals-inc-stock-skyrocketed-today-cm675812,Image source Getty Images What happened Agios Pharmaceuticals NASDAQ AGIO is up 23 at 1 03 p m ET after announcing that its partner Celgene NASDAQ CELG plans to submit an application to the Food and Drug Administration for enasidenib by the end of the year
AGIO,AGIO:UW,BBG004P6MJ59,Biotech Movers: Retrophin Inc (RTRX) and Agios Pharmaceuticals Inc (AGIO),2016-09-07 18:08:11 +0000,http://www.insidermonkey.com/blog/biotech-movers-retrophin-inc-rtrx-and-agios-pharmaceuticals-inc-agio-472852/,Biotech Movers: Retrophin Inc (RTRX) and Agios Pharmaceuticals Inc (AGIO)
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Inc Stock Skyrocketed Today,2016-09-07 17:45:47 +0000,http://www.fool.com/investing/2016/09/07/why-agios-pharmaceuticals-inc-stock-skyrocketed-to.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Agios Pharmaceuticals Inc Stock Skyrocketed Today
AGIO,AGIO:UW,BBG004P6MJ59,"Wednesday's ETF Movers: FBT, GDXJ",2016-09-07 17:17:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-TI24VDrbk/wednesdays-etf-movers-fbt-gdxj-cm675697,In trading on Wednesday the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs up about 1 4 on the day Components of that ETF showing particular strength include shares of Agios Pharmaceuticals up about 24 4 and shares of Seattle Genetics up about 4 8 on the
AGIO,AGIO:UW,BBG004P6MJ59,"Notable Wednesday Option Activity: TRGP, AGIO, WFM",2016-09-07 17:16:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JYi0EuNdGEI/notable-wednesday-option-activity-trgp-agio-wfm-cm675701,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Targa Resources Corp Symbol TRGP where a total of 8 760 contracts have traded so far representing approximately 876 000 underlying shares That amounts to about 57 2 of TRGP
AGIO,AGIO:UW,BBG004P6MJ59,"Tesla, Amazon, and 3 More Stocks Are Capturing the Market’s Attention Today: Here’s Why",2016-09-07 16:32:16 +0000,http://www.insidermonkey.com/blog/tesla-amazon-and-3-more-stocks-are-capturing-the-markets-attention-today-heres-why-472801/,"Tesla, Amazon, and 3 More Stocks Are Capturing the Market’s Attention Today: Here’s Why"
AGIO,AGIO:UW,BBG004P6MJ59,Did Agios Just Speed Up Its Business Plan by 2 Years?,2016-09-07 16:10:10 +0000,http://247wallst.com/healthcare-business/2016/09/07/did-agios-just-speed-up-its-business-plan-by-2-years/,Did Agios Just Speed Up Its Business Plan by 2 Years?
AGIO,AGIO:UW,BBG004P6MJ59,Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene,2016-09-07 12:10:00 +0000,https://www.thestreet.com/story/13696016/1/agios-blood-cancer-drug-heading-to-early-fda-filing-by-partner-celgene.html?puc=yahoo&cm_ven=YAHOO,Agios Blood Cancer Drug Heading to Early FDA Filing by Partner Celgene
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure",2016-09-07 12:02:05 +0000,http://biz.yahoo.com/e/160907/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016",2016-09-06 12:05:38 +0000,http://finance.yahoo.com/news/agios-present-morgan-stanley-global-120538954.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Sept. 06, 2016-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers",2016-08-26 20:03:12 +0000,http://biz.yahoo.com/e/160826/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers"
AGIO,AGIO:UW,BBG004P6MJ59,"ETF’s with exposure to Agios Pharmaceuticals, Inc. : August 26, 2016",2016-08-26 14:15:30 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-agios-pharmaceuticals-inc-august-26-2016/,"ETF’s with exposure to Agios Pharmaceuticals, Inc. : August 26, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,The Implied Analyst 12-Month Target For JKK,2016-08-25 13:46:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2qh9308lPjE/the-implied-analyst-12-month-target-for-jkk-cm669957,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
AGIO,AGIO:UW,BBG004P6MJ59,Stocks Finish Day Firmly In Negative Territory - U.S. Commentary,2016-08-24 16:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P7Hon_ZG3Ls/stocks-finish-day-firmly-in-negative-territory--us-commentary-20160824-00713,Stocks Finish Day Firmly In Negative Territory - U.S. Commentary
AGIO,AGIO:UW,BBG004P6MJ59,Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates,2016-08-19 15:59:37 +0000,http://finance.yahoo.com/news/why-analyst-awaiting-more-efficacy-155937812.html,Why This Analyst Is Awaiting More Efficacy Signals For Agios Pharma Candidates
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh",2016-08-16 20:08:46 +0000,http://biz.yahoo.com/e/160816/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Appoints Andrew Hirsch as Chief Financial Officer,2016-08-16 11:51:02 +0000,http://www.publicnow.com/view/6A27F81C94CFFD097FCF950E9AE2E811050690AD,"[at noodls] - CAMBRIDGE, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Appoints Andrew Hirsch as Chief Financial Officer,2016-08-16 11:30:00 +0000,http://finance.yahoo.com/news/agios-appoints-andrew-hirsch-chief-113000211.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Aug. 16, 2016-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that Andrew Hirsch is joining the company ..."
AGIO,AGIO:UW,BBG004P6MJ59,The 1 Stock You've Been Overlooking for Your Roth IRA,2016-08-11 13:52:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X-PdaRIztwo/the-1-stock-youve-been-overlooking-for-your-roth-ira-cm663892,"Image source  Getty Images.  Americans have a veritable bounty of retirement tools to choose from, but arguably none is better than the Roth IRA .  A Roth IRA is a tax advantaged"
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report",2016-08-08 20:47:00 +0000,http://biz.yahoo.com/e/160808/agio10-q.html,"AGIOS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report"
AGIO,AGIO:UW,BBG004P6MJ59,"ETF’s with exposure to Agios Pharmaceuticals, Inc. : August 8, 2016",2016-08-08 17:47:19 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-agios-pharmaceuticals-inc-august-8-2016/,"ETF’s with exposure to Agios Pharmaceuticals, Inc. : August 8, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus",2016-08-05 19:27:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GANM0bud1sI/agios-agio-q2-loss-wider-than-expected-pipeline-in-focus-cm661286,"Agios Pharmaceuticals, Inc.AGIO reported a second quarter 2016 loss of $1.47 per share, much wider than the Zacks Consensus Estimate of a loss of $1.28 and the year ago loss of 85 cents. Agios Pharmaceuticals Inc. (AGIO) Street EPS"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus",2016-08-05 15:10:03 +0000,http://finance.yahoo.com/news/agios-agio-q2-loss-wider-151003502.html,"Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016",2016-08-05 14:40:19 +0000,http://www.capitalcube.com/blog/index.php/agios-pharmaceuticals-inc-agio-us-earnings-analysis-q2-2016-by-the-numbers-august-5-2016/,"Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016",2016-08-05 11:01:00 +0000,http://finance.yahoo.com/news/agios-present-canaccord-genuity-36th-110100891.html,"[GlobeNewswire] - CAMBRIDGE, Mass., Aug. 05, 2016-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company is scheduled to present ..."
AGIO,AGIO:UW,BBG004P6MJ59,Edited Transcript of AGIO earnings conference call or presentation 4-Aug-16 12:30pm GMT,2016-08-04 19:11:20 +0000,http://finance.yahoo.com/news/edited-transcript-agio-earnings-conference-191120874.html,Edited Transcript of AGIO earnings conference call or presentation 4-Aug-16 12:30pm GMT
AGIO,AGIO:UW,BBG004P6MJ59,BoE Decision Leads To Choppy Trading Ahead Of Jobs Report - U.S. Commentary,2016-08-04 16:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jQnZ5h-bG2Y/boe-decision-leads-to-choppy-trading-ahead-of-jobs-report--us-commentary-20160804-01460,BoE Decision Leads To Choppy Trading Ahead Of Jobs Report - U.S. Commentary
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Reports Wider-than-Expected Loss in Q2,2016-08-04 14:59:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uNw16jI36fI/agios-agio-reports-wider-than-expected-loss-in-q2-cm660315,"Cambridge, MA based Agios Pharmaceuticals, Inc.AGIO is a development stage biopharmaceutical company focused on the development of treatments for cancer and rare genetic metabolic disorders. Currently, the company has several interesting candidates in its pipeline including AG 221 (IDH2"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 2Q loss,2016-08-04 13:43:44 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-reports-2q-loss-134344996.html,Agios Pharmaceuticals reports 2Q loss
AGIO,AGIO:UW,BBG004P6MJ59,Agios (AGIO) Reports Wider-than-Expected Loss in Q2,2016-08-04 12:50:12 +0000,http://finance.yahoo.com/news/agios-agio-reports-wider-expected-125012380.html,Agios (AGIO) Reports Wider-than-Expected Loss in Q2
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today,2016-08-04 12:30:00 +0000,http://biz.yahoo.com/cc/6/153276.html,Agios Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and",2016-08-04 11:22:02 +0000,http://biz.yahoo.com/e/160804/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Second Quarter 2016 Financial Results,2016-08-04 11:12:08 +0000,http://www.publicnow.com/view/11F62C34932D81080211B5117B806F4B8F8E1A38,[at noodls] - - Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by Year-End ...
AGIO,AGIO:UW,BBG004P6MJ59,Q2 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open,2016-08-04 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160804.html?t=agio,Q2 2016 Agios Pharmaceuticals Inc Earnings Release - Before Market Open
AGIO,AGIO:UW,BBG004P6MJ59,"Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More",2016-08-03 16:59:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mlRW8A7KmTY/medical-product-stock-earnings-on-aug-4-nxtm-agio-more-cm659755,Medical is one of the seven sectors in the S&P 500 cohort that is expected to witness earnings growth in the second quarter. The sector is likely to record earnings growth of 3.4% on revenue improvement of 7.7%.  
AGIO,AGIO:UW,BBG004P6MJ59,"Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More",2016-08-03 14:56:02 +0000,http://finance.yahoo.com/news/medical-product-stock-earnings-aug-145602780.html,"Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More"
AGIO,AGIO:UW,BBG004P6MJ59,Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?,2016-08-02 17:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cBlwTZRDtoM/will-agios-agio-disappoint-estimates-in-q2-earnings-cm659007,"Agios Pharmaceuticals, Inc.AGIO is scheduled to report second quarter 2016 results on Aug 4, before the opening bell. Last quarter, the company had posted a positive surprise of 11.59%. Let's see how things are shaping up for this announcement."
AGIO,AGIO:UW,BBG004P6MJ59,Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?,2016-08-02 15:23:03 +0000,http://finance.yahoo.com/news/agios-agio-disappoint-estimates-q2-152303684.html,Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
AGIO,AGIO:UW,BBG004P6MJ59,3 Biotech Stocks to Buy on Sale,2016-07-30 15:24:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/afqjsDuAQgU/3-biotech-stocks-to-buy-on-sale-cm657720,"Image source  Getty Images.  Since last summer, the market has distributed indiscriminate beatings across the biotechnology industry, and companies without approved products to sell have been hardest hit. The iShares Biotechnology ETF (NASDAQ"
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016",2016-07-28 20:01:00 +0000,http://finance.yahoo.com/news/agios-webcast-conference-call-second-200100795.html,"[GlobeNewswire] - CAMBRIDGE, Mass., July 28, 2016-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals draws bullish bet,2016-07-19 17:11:33 +0000,http://finance.yahoo.com/news/agios-pharmaceuticals-draws-bullish-bet-171133663.html,Agios Pharmaceuticals draws bullish bet
AGIO,AGIO:UW,BBG004P6MJ59,"Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact",2016-07-19 11:01:00 +0000,https://www.thestreet.com/story/13642864/1/celgene-jounce-therapeutics-in-early-cancer-immunotherapy-development-pact.html?puc=yahoo&cm_ven=YAHOO,"Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact"
AGIO,AGIO:UW,BBG004P6MJ59,First Week of July 15th Options Trading For Agios Pharmaceuticals (AGIO),2016-07-14 15:29:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XWgj6vpQOj8/first-week-of-july-15th-options-trading-for-agios-pharmaceuticals-agio-cm649186,"Investors in Agios Pharmaceuticals Inc (Symbol AGIO) saw new options begin trading this week, for the July 15th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the AGIO options chain for the new"
AGIO,AGIO:UW,BBG004P6MJ59,Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer,2016-07-13 04:00:00 +0000,http://finance.yahoo.com/news/dr-michael-rosenblatt-joins-flagship-040000842.html,"[PR Newswire] - CAMBRIDGE, Mass., July 13, 2016 /PRNewswire/ -- Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization. He will play a key role in Flagship's internal venture creation team during the conception and launch of the next generation of pioneering biotechnology companies as well as serve as an ongoing strategic resource for all companies in the Flagship ecosystem supporting their clinical development strategies. Dr. Rosenblatt joins Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer since 2009."
AGIO,AGIO:UW,BBG004P6MJ59,"3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016",2016-07-03 21:44:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rUQuCQoR1oc/3-big-reasons-agios-pharmaceuticals-inc-has-plunged-38-in-2016-cm644296,"Image source  Getty Images.  What  Shares of Agios Pharmaceuticals (NASDAQ  AGIO) , a clinical stage biopharmaceutical company focused on the development of cancer therapeutics and drugs to treat metabolic disorders, have"
AGIO,AGIO:UW,BBG004P6MJ59,"3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016",2016-07-03 20:05:00 +0000,http://www.fool.com/investing/2016/07/03/3-big-reasons-agios-pharmaceuticals-inc-has-plunge.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016"
AGIO,AGIO:UW,BBG004P6MJ59,Flagship Ventures Names Daniel McIntyre Partner,2016-06-29 20:47:00 +0000,http://finance.yahoo.com/news/flagship-ventures-names-daniel-mcintyre-204700576.html,"[PR Newswire] - CAMBRIDGE, Mass., June 29, 2016 /PRNewswire/ -- Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies. ""As the innovator in the field of scientific entrepreneurship, Flagship has created a rare community of academic collaborators, financing and business partners, portfolio companies, and a unique ecosystem of science innovation,"" said McIntyre."
AGIO,AGIO:UW,BBG004P6MJ59,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders",2016-06-22 20:10:24 +0000,http://biz.yahoo.com/e/160622/agio8-k.html,"AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders"
AGIO,AGIO:UW,BBG004P6MJ59,"Commit To Purchase Agios Pharmaceuticals At $35, Earn 15.6% Annualized Using Options",2016-06-21 16:56:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dov85DPzrzw/commit-to-purchase-agios-pharmaceuticals-at-35-earn-156-annualized-using-options-cm638508,"Investors eyeing a purchase of Agios Pharmaceuticals Inc (Symbol AGIO) shares, but cautious about paying the going market price of $48.44 share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract"
AGIO,AGIO:UW,BBG004P6MJ59,Agios drug boosts hemoglobin in anemia patients in mid-stage trial,2016-06-14 15:10:19 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/06/agios-drug-boosts-hemoglobin-in-anemia-patients-in.html?ana=yahoo,Agios drug boosts hemoglobin in anemia patients in mid-stage trial
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Favorable Phase II PK Deficiency Study Data,2016-06-13 16:10:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3I5DHO4Gp90/agios-reports-favorable-phase-ii-pk-deficiency-study-data-cm634540,"Agios Pharmaceuticals, Inc.AGIO announced encouraging initial data from an ongoing open label phase II study (DRIVE PK) on one of its pipeline candidates, AG 348, for the treatment of patients suffering from pyruvate kinase (PK) deficiency. Data were presented"
AGIO,AGIO:UW,BBG004P6MJ59,AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency,2016-06-11 12:19:07 +0000,http://www.publicnow.com/view/9F813C167BC80AC44CBF87687A13E7684AA2F608,[at noodls] - - 9 of 18 Total Patients and 9 of 13 Patients with at Least One Missense Mutation Showed Maximal Hemoglobin Increases Between 2.3 to 4.9 g/dL - - AG-348 Well Tolerated with Up to Six Months of Daily Dosing ...
AGIO,AGIO:UW,BBG004P6MJ59,This Is Why Agios Pharmaceuticals' Stock Rose 14.3% in May,2016-06-10 16:12:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ru5UxxYB0DQ/this-is-why-agios-pharmaceuticals-stock-rose-143-in-may-cm633803,"Image source  Getty Images.  What   Shareholders of Agios Pharmaceuticals (NASDAQ  AGIO) , a clinical stage biopharma primarily focused on cancer and rare genetic disorders, had a prosperous May. The company's stock"
AGIO,AGIO:UW,BBG004P6MJ59,Why Agios Pharmaceuticals Inc. Presented Lower Today,2016-06-09 21:14:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KG9H3nKuVk8/why-agios-pharmaceuticals-inc-presented-lower-today-cm633191,"Image source  Getty Images.  What  Oh, what a difference a day makes. Yesterday Agios Pharmaceuticals (NASDAQ  AGIO) was up 7%, presumably in anticipation of data to be presented at the European"
AGIO,AGIO:UW,BBG004P6MJ59,"Thursday's ETF Movers: GDXJ, XBI",2016-06-09 20:11:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8FchP714Luo/thursdays-etf-movers-gdxj-xbi-cm633140,"In trading on Thursday, the Junior Gold Miners ETF ( GDXJ ) is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Fortuna Silver Mines ( FSM ), up"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers,2016-06-09 13:39:06 +0000,http://www.publicnow.com/view/5DEC94190D50AAF86F126E4F01B4020A94291DF6,"[at noodls] - - Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing - - Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation - - Company ..."
AGIO,AGIO:UW,BBG004P6MJ59,AGIO Crosses Above Key Moving Average Level,2016-06-02 17:55:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YefzY0F1UHc/agio-crosses-above-key-moving-average-level-cm629692,"In trading on Thursday, shares of Agios Pharmaceuticals Inc (Symbol AGIO) crossed above their 200 day moving average of $58.79, changing hands as high as $60.20 per share. Agios Pharmaceuticals Inc shares are currently trading up about 3.6% on"
AGIO,AGIO:UW,BBG004P6MJ59,Stocks Close Mostly Higher After Staging Another Recovery - U.S. Commentary,2016-06-02 16:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WN0SslK1P7E/stocks-close-mostly-higher-after-staging-another-recovery--us-commentary-20160602-01093,Stocks Close Mostly Higher After Staging Another Recovery - U.S. Commentary
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Host Conference Call from the 21st Congress of the European Hematology Association,2016-06-01 11:23:01 +0000,http://www.publicnow.com/view/A782D89AD16EE9F7EA81980AD05DD96C520C6FBA,"[at noodls] - CAMBRIDGE, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the ..."
AGIO,AGIO:UW,BBG004P6MJ59,Stocks Climb Well Off Worst Levels But Close In The Red - U.S. Commentary,2016-05-19 16:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A41RnX2lKTw/stocks-climb-well-off-worst-levels-but-close-in-the-red--us-commentary-20160519-01134,Stocks Climb Well Off Worst Levels But Close In The Red - U.S. Commentary
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association,2016-05-19 11:22:06 +0000,http://www.publicnow.com/view/FBE90D5292AF547E94D9D0ED16B17C6745F3C6DE,"[at noodls] - Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study Company to Host Conference Call and Webcast on Saturday, June 11, 2016 CAMBRIDGE, ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Health Care Sector Update for 05/18/2016: AGIO,CELG,PETX,MTP",2016-05-18 17:33:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iCju4HNGamA/health-care-sector-update-for-05182016-agiocelgpetxmtp-cm622944,"Top Health Care Stocks JNJ 0.17% PFE +0.73% MRK +0.24% ABT +0.73% AMGN +0.51% Health care stocks were hanging onto moderate gains this afternoon, with the NYSE Health Care Index adding about 0.4% while shares of health care companies"
AGIO,AGIO:UW,BBG004P6MJ59,Agios Updates 2016 Financial Guidance,2016-05-17 20:12:11 +0000,http://www.publicnow.com/view/24C2D7FD59E292ABBAC41F03F0451F9429E13EB9,[at noodls] - - $200 Million Upfront Payment from Celgene for New Metabolic Immuno-Oncology Collaboration - - Agios Expects 2016 Ending Cash Position of More than $390 Million- - Investor Conference Call Today at 5 ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement,2016-05-17 20:12:11 +0000,http://www.publicnow.com/view/1AD3FB6B20BF82CCB17B36C408B97DFA8B7BB3C9,[at noodls] - - New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment - - AG-120 Rights Outside the United States Transferred to Agios ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 1Q loss,2016-05-05 19:45:55 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-reports-1q-loss-194555925.html,Agios Pharmaceuticals reports 1Q loss
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports First Quarter 2016 Financial Results,2016-05-05 11:21:04 +0000,http://www.publicnow.com/view/32476D4F1B89FC47C9E6106791CFB9F824AB08A0,"[at noodls] - Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study Enrollment Complete in AG-221 ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016",2016-05-02 13:00:08 +0000,http://www.publicnow.com/view/C5D066CB9118EC9F07DE5A93025EADF746F10428,"[at noodls] - CAMBRIDGE, Mass., May 02, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy,2016-03-30 11:30:23 +0000,http://www.publicnow.com/view/D89E7525CAC368A209D2AB4ADC428807D384C249,"[at noodls] - CAMBRIDGE, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 4Q loss,2016-02-18 14:13:27 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-reports-4q-loss-141327214.html,Agios Pharmaceuticals reports 4Q loss
AGIO,AGIO:UW,BBG004P6MJ59,Agios Outlines Key 2016 Goals and Priorities,2016-01-11 12:47:20 +0000,http://www.noodls.com/view/0FDB79B04A64E44F8613462A1496BB8E07F268F5,[at noodls] - - Complete Enrollment of 125-Patient Expansion Cohorts for AG-221 and AG-120 in Relapsed/Refractory Acute Myeloid Leukemia in Second Half of 2016 - - Present First Data from Phase 2 DRIVE PK Study for ...
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11",2016-01-04 13:38:01 +0000,http://www.noodls.com/view/C54741A16AF74787475BEC69B438D523E3980561,"[at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the 34 Annual in on at (). ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients,2015-12-18 12:52:28 +0000,http://www.noodls.com/view/F1BCD4F9F1FBFBB3A8FA5D4AF9EC035673CDEC75,"[at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies,2015-12-06 21:52:08 +0000,http://www.noodls.com/view/48D038C473FBFBFF0B4CDEFB0C1AB1BC74310395,[at noodls] - - Patients on Study for up to 18 Months with a Median Response Duration of 6.9 Months in Relapsed/Refractory Acute Myeloid Leukemia (AML) - - Enrollment Complete for Four 25-Patient Expansion Cohorts; ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies,2015-12-05 14:26:12 +0000,http://www.noodls.com/view/ACD218A3E0DB1DF4117E6F4585A5A697497A30B4,[at noodls] - - Patients on Study for up to 14.1 Months with a Median Response Duration of 5.6 Months - - Four Phase 1 Expansion Cohorts Enrolling; Planned Global Registration-enabling Phase 3 Study On Track - - Company ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors,2015-11-08 13:16:10 +0000,http://www.noodls.com/view/22FF4C957FE7959B458F62CBB25BB08DFE850298,"[at noodls] - - Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose Selected - - Phase 1 Expansion Cohorts for Patients with IDH1 Mutant Positive Glioma, Cholangiocarcinoma, ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting,2015-11-05 15:20:07 +0000,http://www.noodls.com/view/12B0071265D591EEBB5440F94C4F59D49B371DD1,[at noodls] - - New Safety and Efficacy Data from Ongoing Studies of AG-221 and AG-120 to be Highlighted in Oral and Poster Presentations - - Posters to Feature Pharmacokinetics and Pharmacodynamics Data for AG-348 ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Reports Third Quarter 2015 Financial Results,2015-11-05 12:20:19 +0000,http://www.noodls.com/view/166FC89316C626B0B46DE7188FE57EEB51E3C585,[at noodls] - - New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting - - R&D Day Highlights Included Initiation of AG-221 Phase 3 'IDHENTIFY' ...
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals reports 3Q loss,2015-11-05 12:19:37 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-reports-3q-loss-121937348.html,Agios Pharmaceuticals reports 3Q loss
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10",2015-11-03 12:46:03 +0000,http://www.noodls.com/view/66F1E7A7F619847113E6268393CC0F119D898454,"[at noodls] - CAMBRIDGE, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company ..."
AGIO,AGIO:UW,BBG004P6MJ59,"Agios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015",2015-10-29 11:38:14 +0000,http://www.noodls.com/view/E45AA7E09B9052AD57F47A4AC9C02363FE8BA602,"[at noodls] - CAMBRIDGE, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the ..."
AGIO,AGIO:UW,BBG004P6MJ59,Agios Pharmaceuticals posts 3Q profit,2014-11-07 12:09:34 +0000,http://sg.finance.yahoo.com/news/agios-pharmaceuticals-posts-3q-profit-120934213--finance.html,Agios Pharmaceuticals posts 3Q profit
